Revvity (RVTY) 10-K risk factor changes: FY2024 vs FY2023

[removed: Our quarterly revenue and results] of operations are highly dependent on the volume and timing of orders received during the quarter.

Negative fluctuations in our customers’ markets, the inability of our customers to secure credit or funding, restrictions in capital expenditures, general economic conditions, cuts in government [added: funding, deficit reduction efforts or other actions that reduce or freeze the availability of government] funding [added: for healthcare and research] or unfavorable changes in government regulations would likely result in a reduction in demand for our products and [removed: services.][added: services and additional pricing pressures, as well as create potential collection risk associated with those sales.]

Our revenues may be adversely affected if our customers delay or reduce purchases as a result of uncertainties surrounding the approval of government or industrial funding [removed: proposals.][added: proposals or reductions in government funding.]

Our growth and profitability [removed: is] [added: are] subject to global economic and political conditions, and operational disruptions at our facilities.

Our business is affected by global economic and political conditions as well as the state of the financial markets, particularly as the United States and other countries balance concerns around debt, inflation, [added: trade protectionism,] growth and budget allocations in their policy initiatives.

Environmental events and political changes, including [added: trade barriers and tariffs, and] war or other conflicts, such as the current conflicts in Ukraine and the Middle East, some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.

If we fail to accurately foresee our customers’ needs and future activities, we may invest heavily in research and development of [removed: products that do not lead to significant revenue.]

[added: We may also incur expenses related to completing] acquisitions or licensing technologies, or in evaluating potential acquisitions or technologies, which may adversely impact our profitability.

- contract [removed: termination] [added: terminations, adverse litigation outcomes,] and litigation costs,

In addition, global health crises or pandemics, [added: changes in trade policy,] wars, conflicts, or other changes in a country’s or region’s political or economic conditions, could have a significant adverse effect on our supply chain.

[removed: As a result of these rules, we may incur] additional costs in complying with the disclosure requirements and in satisfying those customers who require that the components used in our products be certified as conflict-free, and the potential lack of availability of these materials at competitive prices could increase our production costs.

If we were to experience a prolonged system disruption in the information technology systems that involve our interactions with customers, suppliers or other third parties, it could result in the loss of sales and customers and significant [added: incremental costs, which could adversely affect our business.]

As of December [removed: 31, 2023,] [added: 29, 2024,] our total assets included [removed: $9.6] [added: $9.1] billion of net intangible assets.

Net intangible assets consist principally of goodwill associated with acquisitions and costs associated with securing patent rights, trademark rights, customer relationships, core technology and technology [removed: licenses and in-process research and development,] [added: licenses,] net of accumulated amortization.

We test goodwill at least annually for potential impairment by comparing the carrying value to the fair [removed: market] value of the reporting unit to which [removed: they are] [added: it is] assigned.

[removed: The legislative and regulatory landscape for privacy and data protection continues to] evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business.

If we fail to comply with applicable laws and regulations, we could suffer civil and criminal damages, fines and penalties, exclusion from participation in governmental healthcare [added: programs, and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur liabilities from third-party claims, all of which could have a significant adverse effect on our business.]

Our sales originating outside the United States represented the majority of our total revenue in fiscal year [removed: 2023.][added: 2024.]

Our senior unsecured revolving credit facility, senior unsecured notes due in [removed: 2024 (“2024 Notes”), senior unsecured notes due in] 2026 (“2026 Notes”), senior unsecured notes due in 2028 (“2028 Notes”), senior unsecured notes due in 2029 (“2029 Notes”), senior unsecured notes due in [added: March] 2031 (“March 2031 Notes”), senior unsecured notes due in [added: September] 2031 (“September 2031 Notes”) and senior unsecured notes due in 2051 (“2051 Notes”) include restrictive covenants that limit our ability to engage in activities that could otherwise benefit our company.

Our failure to comply with any of the restrictions in our senior unsecured revolving credit facility, the [removed: 2024 Notes, the] 2026 Notes, the 2028 Notes, the 2029 Notes, the March 2031 Notes, the September 2031 Notes, the 2051 [removed: Notes] [added: Notes, including our new senior unsecured revolving credit facility that was entered into in January 2025,] or any future indebtedness may result in an event of default under those debt instruments, which [removed: could permit acceleration of the debt under those debt instruments, and require us to prepay that debt before its scheduled due date under certain circumstances.]

On October [removed: 26, 2023,] [added: 24, 2024,] we announced that our Board of Directors (our “Board”) had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year [removed: 2023] [added: 2024] that was paid in February [removed: 2024.][added: 2025.]

On January [removed: 25, 2024,] [added: 23, 2025,] we announced that our Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year [removed: 2024] [added: 2025] that will be payable in May [removed: 2024.][added: 2025.]

Our quarterly revenue and results

products that do not lead to significant revenue.

- changes in trade policy applicable to the regions in which we do business,

As a result of these rules, we may incur

The legislative and regulatory landscape for privacy and data protection continues to

could permit acceleration of the debt under those debt instruments, and require us to prepay that debt before its scheduled due date under certain circumstances.

We may also incur expenses related to completing

incremental costs, which could adversely affect our business.

programs, and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur liabilities from third-party claims, all of which could have a significant adverse effect on our business.

Each of the fiscal years ended December [added: 29, 2024 (“fiscal year 2024”), December] 31, 2023 (“fiscal year [removed: 2023”),] [added: 2023”) and] January 1, 2023 (“fiscal year 2022”) [removed: and January 2, 2022 (“fiscal year 2021”)] included 52 weeks.

The fiscal year ending December [removed: 29, 2024] [added: 28, 2025] (“fiscal year [removed: 2024”)] [added: 2025”)] will include 52 weeks.

Overview of Fiscal Year [removed: 2023][added: 2024]

During fiscal year [removed: 2023,] [added: 2024,] we [added: again] delivered differentiated [added: financial] performance despite market headwinds, demonstrating the strength of our product [removed: portfolio, continued innovation,] [added: portfolio] and [removed: investments in our people.][added: innovation.]

Our overall revenue in fiscal year [removed: 2023 decreased] [added: 2024 increased] by [removed: $561.3] [added: $4.5] million, or [removed: 17%,] [added: less than 1%,] as compared to fiscal year [removed: 2022,] [added: 2023,] reflecting [removed: a decrease] [added: an increase] of [removed: $560.7] [added: $42.7] million, or [removed: 28%,] [added: 3%,] in Diagnostics segment revenue and a decrease of [removed: $0.6] [added: $38.2] million, or [removed: less than 1%,] [added: 3%,] in Life Sciences segment revenue.

The [removed: decrease] [added: increase] in Diagnostics segment revenue was primarily driven by [removed: decreased] [added: increased] demand [removed: for COVID-19 product offerings,] [added: in our immunodiagnostics and reproductive health businesses,] partially offset by [removed: growth] [added: a decrease] in [removed: the core immunodiagnostics] [added: revenue from our applied genomics] business.

The decrease in Life Sciences segment revenue was driven by a decrease in instruments [added: and reagents] revenue due to pharmaceutical and biotechnology market [removed: headwinds and a decrease] [added: headwinds, partially offset by an increase] in software revenue from the timing of contract [removed: renewals, partially offset by an increase in reagents revenue.][added: renewals and new orders.]

Our consolidated gross [removed: margins] [added: margin] decreased [removed: 411] [added: 16] basis points in fiscal year [removed: 2023,] [added: 2024,] as compared to fiscal year [removed: 2022,] [added: 2023,] primarily due to [removed: lower revenue from COVID-19 product offerings, and] an unfavorable shift in product [removed: mix,] [added: mix and higher product costs,] partially offset by pricing [removed: actions.][added: actions and productivity initiatives.]

Revenue for fiscal year [removed: 2023] [added: 2024] was [removed: $2,750.6] [added: $1,254.1] million, as compared to [removed: $3,311.8] [added: $1,292.3] million for fiscal year [removed: 2022,] [added: 2023,] a decrease of [removed: $561.3] [added: $38.2] million, or [removed: 17%.][added: 3%.]

The analysis in the remainder of this paragraph compares segment revenue for fiscal year [removed: 2023] [added: 2024] as compared to fiscal year [removed: 2022] [added: 2023] and includes the effect of foreign exchange rate fluctuations.

Diagnostics segment revenue for fiscal year [removed: 2023] [added: 2024] was [removed: $1,459.1] [added: $1,500.9] million, as compared to [removed: $2,019.7] [added: $1,458.2] million for fiscal year [removed: 2022, a decrease] [added: 2023, an increase] of [removed: $560.7] [added: $42.7] million, or [removed: 28%,] [added: 3%,] due to [removed: a decrease] [added: an increase] of [removed: $380.3] [added: $43.7] million in immunodiagnostics [removed: revenue, a decrease] [added: revenue and an increase] of [removed: $165.2] [added: $22.6] million in [removed: applied genomics revenue and] [added: reproductive health revenue, partially offset by] a decrease of [removed: $15.3] [added: $23.7] million in [removed: reproductive health] [added: applied genomics] revenue.

Life Sciences segment revenue was [removed: $1,292.3] [added: $1,254.1] million for fiscal year [removed: 2023,] [added: 2024,] as compared to [removed: $1,292.9] [added: $1,292.3] million for fiscal year [removed: 2022,] [added: 2023,] a decrease of [removed: $0.6] [added: $38.2] million, or [removed: less than 1%,] [added: 3%,] driven by a decrease of [removed: $24.3] [added: $47.2] million in instruments revenue and a decrease of [removed: $17.7] [added: $13.5] million in [removed: software] [added: reagents] revenue, partially offset by an increase of [removed: $41.4] [added: $22.5] million in [removed: reagents] [added: software] revenue.

Cost of revenue for fiscal year [removed: 2023] [added: 2024] was [removed: $1,210.9] [added: $1,217.4] million, as compared to [removed: $1,322.0] [added: $1,210.9] million for fiscal year [removed: 2022, a decrease] [added: 2023, an increase] of approximately [removed: $111.1] [added: $6.5] million, or [removed: 8%.][added: 1%.]

[removed: 2023] [added: As a percentage of revenue, cost of revenue increased to 44.2% in fiscal year 2024] from [removed: 40%] [added: 44.0%] in fiscal year [removed: 2022,] [added: 2023,] resulting in a decrease in gross margin of approximately [removed: 411] [added: 16] basis points to [removed: 56%] [added: 55.8%] in fiscal year [removed: 2023] [added: 2024] from [removed: 60%] [added: 56.0%] in fiscal year [removed: 2022] [added: 2023] due to [removed: lower COVID-19 revenue and] an unfavorable shift in product [removed: mix,] [added: mix and higher product costs,] partially offset by pricing [removed: actions.][added: actions and productivity initiatives.]

Stock compensation expense related to awards given to BioLegend employees post-acquisition added an incremental expense of [removed: $2.8] [added: $0.6] million for fiscal year [removed: 2023,] [added: 2024,] as compared to [removed: $5.6] [added: $2.8] million for fiscal year [removed: 2022.][added: 2023.]

The above decreases were partially offset by an increase in [removed: amortization of intangible assets] [added: asset impairments,] which [removed: was $147.6 million for fiscal year 2023, as compared to $141.6] [added: added an incremental expense of $22.8] million for fiscal year [removed: 2022.][added: 2024.]

Selling, general and administrative expenses for fiscal year [removed: 2023] [added: 2024] were [removed: $1,022.6] [added: $994.1] million, as compared to [removed: $1,025.5] [added: $1,022.6] million for fiscal year [removed: 2022,] [added: 2023,] a decrease of [removed: approximately $3.0] [added: $28.5] million, or [removed: 0.3%.][added: 3%.]

As a percentage of revenue, selling, general and administrative expenses [removed: increased] [added: decreased] to [removed: 37%] [added: 36.1%] in fiscal year [removed: 2023] [added: 2024] from [removed: 31%] [added: 37.2%] in fiscal year [removed: 2022.][added: 2023.]

Amortization of intangible assets decreased and was [removed: $217.5] [added: $215.0] million for fiscal year [removed: 2023,] [added: 2024,] as compared to [removed: $229.1] [added: $217.5] million for fiscal year [removed: 2022.][added: 2023.]

Purchase accounting adjustments [removed: added an incremental expense of $4.3] [added: decreased expenses by $1.7] million for fiscal year [removed: 2023,] [added: 2024,] which primarily consisted of a change in [added: fair value of] contingent consideration, as compared to [removed: decreasing] [added: increasing] expenses by [removed: $1.2] [added: $4.3] million for fiscal year [removed: 2022.][added: 2023.]

[removed: Legal costs for significant] [added: Significant] litigation matters and [removed: settlements, net] [added: settlements added an incremental expense] of [removed: reversals, were minimal] [added: $7.8 million] for fiscal year [removed: 2023, as compared to decreasing expenses by $0.6 million] [added: 2024 and were minimal] for fiscal year [removed: 2022.][added: 2023.]

Acquisition and divestiture-related expenses, which primarily consisted of [removed: rebranding,] legal and integration [removed: costs] [added: costs,] and stock compensation expense related to the awards given to BioLegend employees post-acquisition, added an incremental expense of [removed: $62.0] [added: $16.3] million for fiscal year [removed: 2023,] [added: 2024,] as compared to [removed: $28.9] [added: $62.0] million for fiscal year [removed: 2022.][added: 2023.]

Restructuring and [removed: other,] [added: other costs,] net, [removed: increased] [added: decreased] and [removed: was $26.6] [added: were $17.5] million for fiscal year [removed: 2023,] [added: 2024,] as compared to [removed: $13.6] [added: $26.6] million for fiscal year [removed: 2022.][added: 2023.]

Excluding the factors above, the net decrease in selling, general and administrative expenses was the result of [removed: cost containment and] productivity [removed: initiatives.][added: initiatives and cost containment.]

Research and development expenses for fiscal year [removed: 2023] [added: 2024] were [removed: $216.6] [added: $196.8] million, as compared to [removed: $221.6] [added: $216.6] million for fiscal year [removed: 2022,] [added: 2023,] a decrease of [removed: $5.0] [added: $19.7] million, or [removed: 2%.][added: 9%.]

As a percentage of revenue, research and development expenses [removed: increased] [added: decreased] to [removed: 8%] [added: 7.1%] in fiscal year [removed: 2023] [added: 2024] from [removed: 7%] [added: 7.9%] in fiscal year [removed: 2022.][added: 2023.]

The decrease in research and development expenses was primarily driven by [removed: a cost containment and] productivity [removed: initiatives,] [added: initiatives and cost containment,] as well as a decrease in stock compensation expense related to awards given to BioLegend employees post-acquisition, which [removed: was] [added: added] an [added: incremental] expense of [removed: $4.3] [added: $2.2] million in fiscal year [removed: 2023,] [added: 2024,] as compared to [removed: $5.4] [added: $4.3] million for fiscal year [removed: 2022.][added: 2023.]

| | | | December [removed: 31, 2023] [added: 29, 2024] | | | | | | [removed: January 1,] [added: December 31,] 2023 | | | | | | [removed: | | | | | |] [added: January 1, 2023] | | |

| Interest income | | | $ | [removed: (72,131)] [added: (73,190)] | | | | | $ | [removed: (3,589)] [added: (72,131)] | | | | | | | | | | | | | |

| Change in fair value of [removed: financial securities] [added: investments] | | | [removed: 33,921] [added: (7,958)] | | | | | | [removed: 15,754] [added: 33,921] | | | | | | | | | | | | | | |

| Other components of net periodic pension cost [removed: (credit)] | | | [removed: 19,006] [added: 8,508] | | | | | | [removed: (33,158)] [added: 19,006] | | | | | | | | | | | | | | |

| Foreign exchange losses and other expense, net | | | [removed: 37,977] [added: 6,977] | | | | | | [removed: 7,900] [added: 37,977] | | | | | | | | | | | | | | |

| Total interest and other expense, net | | | $ | [removed: 117,586] [added: 30,615] | | | | | $ | [removed: 90,862] [added: 117,586] | | | | | | | | | | | | | |

Other components of net periodic pension cost [removed: increased] [added: decreased primarily] due to [removed: the decreases] [added: increases] in [removed: the] applicable discount rates.

Foreign exchange losses and other expense, net, [removed: increased] [added: was lower during fiscal year 2024 as compared to the same period in the prior year] primarily due to a foreign exchange loss of $24.0 million [removed: for the] [added: that was recognized in] fiscal year 2023 related to the cash proceeds from the sale of the Business [removed: that were held offshore.]

Interest income increased due to an increase in [added: short-term] investments and higher interest rates.

The effective tax rates [removed: on continuing operations] were [removed: 1.9%] [added: 10.5%] and [removed: 21.3%] [added: 1.9%] for fiscal years [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] respectively.

| | | | December [added: 29, 2024 | | | | | | December] 31, 2023 | | | | | | [removed: January 1, 2023] | | | | | | [added: | | |]

| Tax at statutory rate | | | $ | [removed: 38,346] [added: 66,386] | | | | | $ | [removed: 136,886] [added: 38,346] | | | | |

| Non-U.S. rate differential, net | | | [removed: (18,479)] [added: (13,332)] | | | | | | [removed: (5,221)] [added: (18,479)] | | | | | |

Our consolidated operating margin increased 166 basis points in fiscal year 2024, as compared to fiscal year 2023, due to productivity initiatives and cost containment.

As a result of adjustments to deferred revenue related to certain acquisitions required by business combination accounting rules, we did not recognize $0.8 million of revenue for each of the fiscal years 2024 and 2023 that otherwise would have been recorded by the acquired businesses during each of the respective periods.

Rebranding costs were $6.2 million for fiscal year 2024.

Amortization of intangible assets was $144.4 million for fiscal year 2024, as compared to $147.6 million for fiscal year 2023.

| Interest expense | | | 96,278 | | | | | | 98,813 | | | | | | | | | | | | | | |

Interest expense decreased primarily due to lower debt balance as a result of the repayment of senior unsecured notes that matured in September 2023 and September 2024.

Change in fair value of investments resulted in income of $8.0 million in fiscal year 2024 as compared to expense of $33.9 million in fiscal year 2023 primarily due to the fluctuation in share price of investments in marketable securities, partially offset by fair value changes in notes receivables and other investments.

that were held offshore.

The variation in our effective tax rate from the statutory rate for fiscal year 2024 was primarily the result of general business tax credits of $17.6 million, a prior year true-up related to the tax on foreign earnings of approximately $9.4 million, and favorability in our U.S. taxation of multinational operations of $28.9 million, which were partially offset by an increase in valuation allowance of $29.8 million.

The variation in our effective tax rate from the statutory tax rate for fiscal year 2023 was primarily the result of a favorable ruling from a foreign tax authority of approximately $15.2 million, a prior year true-up related to the tax on foreign earnings of approximately $7.0 million, and a benefit for the state tax rate change on deferred taxes of $12.8 million, which were partially offset by an increase in tax reserves of approximately $33.2 million in respect of unfavorable developments with respect to an uncertain tax position with a foreign tax authority that was partially related to continuing operations.

Segment operating margin increased 286 basis points in fiscal year 2024, as compared to fiscal year 2023, primarily due to higher volume, productivity initiatives, and cost containment.

During the fiscal year 2024, we received $18.8 million of the Brand Fee.

We expect to receive the remaining balance of the Brand Fee in installments in 2025.

During fiscal year 2024, we received approximately $138.5 million of cash from the Purchaser and recognized a loss of $19.8 million primarily related to post-closing adjustments.

During fiscal year 2024, we recognized $25.4 million of other expense primarily due to the adjustment to the receivable related to the post-closing adjustment and divestiture-related costs in gain on sale.

The cash provided by operating activities for fiscal year 2024 was principally a result of income from continuing operations of $283.1 million, adjustments for non-cash charges aggregating to $400.2 million, including depreciation and amortization of $427.8 million, and a net cash decrease in working capital of $18.3 million.

Contingent consideration payments of $6.1 million during fiscal year 2024 as compared to $0.6 million during fiscal year 2023 were included in cash flows from operating activities.

During fiscal year 2024, proceeds from maturity of U.S. treasury securities were $710.0 million and proceeds from investments and notes receivables were $2.5 million.

During fiscal year 2023, purchases of investments in U.S. treasury securities amounted to $1.2 billion, and net cash used for acquisitions was $2.1 million, which were partially offset by proceeds from maturity of U.S. treasury securities totaling $550.0 million.

During fiscal year 2024, we received proceeds of $710.0 million upon the maturity of all our outstanding U.S. Treasury securities and utilized those proceeds to partially repay the outstanding 2024 Notes.

In addition, on January 7, 2025, our prior senior unsecured revolving credit facility was cancelled and replaced with a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through January 7, 2030.

We project an increase in capital expenditures in fiscal year 2025 relative to fiscal year 2024.

This planned increase reflects our strategic commitment to enhancing our digital capabilities, product innovations, and realigning our production infrastructure.

We anticipate funding these initiatives through a combination of our existing cash reserves and internally generated funds from our continuing operations, ensuring a prudent approach to financial management while pursuing these critical growth and optimization strategies.

We recorded the applicable taxes associated with the future remittance of undistributed foreign earnings previously taxed at the U.S. federal level and/or that would be claimed for a dividend received deduction if repatriated.

In connection with the sale of the Business, we expect to receive the remaining balance related to the Brand Fee of $56.3 million as of December 29, 2024, in installments through fiscal year 2025.

No shares remain available for repurchase under the Repurchase Program due to its termination.

During the fiscal year 2024, we received $18.8 million of the Brand Fee.

During the fourth quarter of fiscal year 2024, we voluntarily changed our annual goodwill impairment testing date from the later of January 1 or the first day of each fiscal year to the later of November 1 or the first day of our eleventh fiscal month of each fiscal year.

We changed the measurement date to more closely align the annual impairment testing date with the most current information from the budgeting and strategic planning process.

We believe the change in goodwill impairment testing date does not represent a material change to our method of applying the accounting principle in light of our internal controls and requirements to assess goodwill impairment upon certain triggering events.

This change was applied prospectively and therefore, we performed our annual impairment testing for our reporting units for fiscal year 2024 as of January 1, 2024 and November 1, 2024.

A number of significant estimates are involved in the application of the income approach to arrive at forecasted cash flows.

As of the November 1, 2024 impairment testing, the fair value of each of our reporting units substantially exceeded the respective carrying value of each reporting unit with the exception of the Life Sciences reporting unit.

The Life Sciences reporting unit, which had a goodwill balance of $4,332.5 million at December 29, 2024, had a fair value that exceeded its carrying value by more than 10% but less than 20% as of the November 1, 2024 impairment testing date.

Retirement and post-retirement benefit plans are a significant cost of doing business, and

| | | | \-0.25 | | | | | | 6,280 | | | | | | 1,747 | | |

Our consolidated operating margin decreased 1,150 basis points in fiscal year 2023, as compared to fiscal year 2022, also due to lower revenue from COVID-19 product offerings and unfavorable shift in product mix, partially offset by operating expense reductions.

As a percentage of revenue, cost of revenue increased to 44% in fiscal year

The amortization of purchase accounting adjustments to record the inventory from certain acquisitions added an incremental expense of $45.3 million for fiscal year 2022.

The decreased expenses were partially offset by our investments in new product development.

| Interest expense including costs of bridge financing | | | 98,813 | | | | | | 103,955 | | | | | | | | | | | | | | |

The increase of $26.7 million in interest and other expense, net, in fiscal year 2023 as compared to fiscal year 2022 was primarily due to an increase in other components of net periodic pension cost of $52.2 million, an increase in foreign exchange losses and other expense, net of $30.1 million and an increase in the change in fair value of financial securities of $18.2 million.

These increases in interest and other expense, net, were partially offset by an increase in interest income of $68.5 million and a decrease of $5.1 million in interest expense.

Interest expense decreased due to $3.7 million of debt extinguishment income for the fiscal year 2023, as compared to $2.9 million of debt extinguishment income for the fiscal year 2022, as well as a result of an overall decrease in debt.

The lower than expected 2023 tax rate will not repeat in 2024.

Certain countries in which we have operations have adopted legislation or are expected to adopt legislation influenced by the OECD Pillar Two rules, which imposes a minimum tax rate of 15% among other requirements.

We will continue to evaluate the potential consequences of Pillar Two legislation on our effective tax rate as the legislation and related interpretations of OECD guidance continues to evolve.

Segment operating margin decreased 100 basis points in fiscal year 2023, as compared to fiscal year 2022, primarily due to an unfavorable shift in product mix, partially offset by pricing actions.

We also recorded a receivable of approximately $160.2 million as of December 31, 2023 for post-closing adjustments that are expected to be settled with the Purchaser during fiscal year 2024.

The final amount of the receivable related to the post-closing adjustments is subject to change.

During fiscal year 2023, we recognized an increase in provision for income taxes of $242.8 million, primarily related to the taxes on the gain on sale of the Business.

During fiscal year 2023, we recognized $36.0 million of divestiture-related costs in selling, general and administrative expenses in discontinued operations, as compared to $69.4 million during fiscal year 2022.

However, we expect to use external sources to satisfy the balance of our debt when due, any larger acquisitions and other long-term liabilities, such as contributions to our postretirement benefit plans.

Additionally, we purchased U.S. treasury securities whose proceeds upon maturity are intended to be utilized to repay outstanding debt securities, including our 0.850% senior unsecured notes due in September 2024 (the “2024 Notes”), which had $711.5 million in outstanding principal as of December 31, 2023.

During fiscal year 2023, we contributed $10.0 million to our pension plan in the United States and $7.6 million, in the aggregate, to pension plans outside of the United States.

During fiscal year 2023, we made purchases of investments in U.S. treasury securities totaling $1,221.6 million.

The capital expenditures in each period were primarily for manufacturing, software, and other capital equipment purchases.

maturity of U.S. treasury securities totaling $550.0 million, and proceeds from disposition of businesses and assets totaling $0.2 million.

The cash used in investing activities during fiscal year 2022 was partially offset by proceeds from notes receivable totaling $8.9 million, and proceeds from disposition of businesses and assets totaling $14.5 million.

The changes in both periods reflect our intentions to pay down debt, which we expect to continue throughout fiscal year 2024.

We paid $0.8 million in settlement of hedges in fiscal year 2022.

Since the beginning of the third quarter of fiscal year 2022, we have repurchased $88.5 million in aggregate principal amount of our 2024 Notes.

At December 31, 2023, we had investments in U.S. treasury securities with a carrying amount of $689.9 million whose proceeds upon maturity are intended to be utilized to repay the outstanding 2024 Notes.

During fiscal year 2024, we expect to invest an amount for capital expenditures similar to that in fiscal year 2023, primarily to introduce new products, to improve our operating processes, to shift the production capacity to lower cost locations, and to develop information technology.

We expect to use our available cash and internally generated funds to fund these expenditures.

We had no other liquid investments at December 31, 2023.

At December 31, 2023, we had investments in U.S. treasury securities with a carrying amount of $689.9 million whose proceeds upon maturity are intended to be utilized to repay our outstanding 2024 Notes.

In connection with the sale of the Business, we are entitled to an additional $75.0 million in proceeds as consideration for our ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the Purchaser.

This consideration is expected to be received in installments through the first half of 2025.

In addition, we have also recorded a receivable of approximately $160.2 million as of December 31, 2023 for post-closing adjustments related to the sale of the Business that is expected to be received during fiscal year 2024.

During the fiscal year ended December 31, 2023, we repatriated approximately $1.6 billion of foreign cash to the United States.

Distressed global financial markets could adversely impact general economic conditions by reducing liquidity and credit availability, creating increased volatility in security prices, widening credit spreads and decreasing valuations of certain investments.

The widening of credit spreads may create a less favorable environment for certain of our businesses and may affect the fair value of financial instruments that we issue or hold.

Increases in credit spreads, as well as limitations on the availability of credit at rates we consider to be reasonable, could affect our ability to borrow under future potential facilities on a secured or unsecured basis, which may adversely affect our liquidity and results of operations.

In difficult global financial markets, we may be forced to fund our operations at a higher cost, or we may be unable to raise as much funding as we need to support our business activities.

Our pension plans have not experienced a material impact on liquidity or counterparty exposure due to the volatility and uncertainty in the credit markets.

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and cash equivalents, derivatives, marketable [removed: securities and] [added: securities,] accounts [removed: receivable.][added: receivable and notes receivables.]

We believe we had no significant concentrations of credit risk as of December [removed: 31, 2023.][added: 29, 2024.]

We [added: only] use derivative instruments as part of our risk management strategy [removed: only, and includes] [added: including] derivatives utilized as economic hedges that are not designated as hedging instruments.

In the ordinary course of business, we enter into foreign exchange contracts for periods consistent with [removed: its] [added: our] committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies.

We held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling [removed: $412.1] [added: $409.8] million at December [removed: 31, 2023] [added: 29, 2024] and [removed: $476.9] [added: $412.1] million at [removed: January 1,] [added: December 31,] 2023, and the fair value of these foreign currency derivative contracts was insignificant.

During fiscal year 2018, we designated a portion of the 2026 Notes to hedge [removed: its] [added: our] investments in certain foreign subsidiaries.

[removed: Unrealized] translation [removed: adjustments from a portion of the 2026 Notes were included in the foreign currency translation] component of accumulated other comprehensive income (“AOCI”), which offsets translation adjustments on the underlying net assets of foreign subsidiaries.

As of December [removed: 31, 2023,] [added: 29, 2024,] the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €498.6 million.

The unrealized foreign exchange (gains) losses recorded in AOCI related to the net investment hedge were [removed: $19.5] [added: $(31.7)] million, [removed: $34.5] [added: $19.5] million and [removed: $(33.2)] [added: $(34.5)] million during the fiscal years [removed: 2023, 2022] [added: 2024, 2023] and [removed: 2021,] [added: 2022,] respectively.

See Note [removed: 19,] [added: 18,] *Derivatives and Hedging Activities,* in the Notes to Consolidated Financial Statements for a detailed discussion of our derivative instruments and hedging activities.

As of December [removed: 31, 2023,] [added: 29, 2024,] this computation estimated that there is a 5% chance that the market value of the underlying exposures and the corresponding derivative instruments either increase or decrease due to foreign currency fluctuations by more than [removed: $2.9] [added: $1.8] million.

Specifically, during each of the four quarters ended in fiscal year [removed: 2023,] [added: 2024,] the Value-At-Risk ranged between [removed: $0.9] [added: $1.0] million and [removed: $2.9] [added: $1.8] million, with an average of approximately [removed: $1.6] [added: $1.5] million.

[removed: As of December 31, 2023, our investments in U.S. treasury securities of $689.9 million earn fixed interest rates, however, the invested portion of our] [added: Our] cash and cash equivalents, for which we receive interest at variable rates, [removed: was $913.2 million.][added: were $1,163.4 million at December 29, 2024.]

However, no such instruments are outstanding at December [removed: 31, 2023.][added: 29, 2024.]

[removed: (i)] Changes in interest rates can cause our interest expense and cash flows to fluctuate to the extent we have borrowing outstanding on our revolving credit facility.

[removed: (ii) Changes] [added: ii.Changes] in interest rates can cause our interest income and cash flows to fluctuate.

Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency

*Interest Rate Risk.* Our debt portfolio is primarily comprised of fixed interest debt; however, there is $0.5 million of variable rate instruments.

i.

In addition, in connection with certain intercompany loan agreements utilized to finance our acquisitions and stock repurchase program, we enter into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies.

We record these hedges at fair value on our consolidated balance sheets.

The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net.

The cash flows related to the settlement of these hedges are included in cash flows from financing activities within our consolidated statements of cash flows.

*Interest Rate Risk.* As of December 31, 2023, we had no outstanding borrowings under our senior unsecured revolving credit facility which bears interest at a variable rate.

Substantially all of our debt portfolio is comprised of fixed interest debt.

As of December [removed: 31, 2023,] [added: 29, 2024,] we employed approximately [removed: 11,500] [added: 11,000] employees.

We partner with global pharmaceutical, biotech and contract research organizations, as well as academic [added: and government] institutions, to enable them to discover and develop better treatments and therapeutics to fight disease faster and more efficiently.

[removed: *•*Radiometric] [added: ◦Radiometric] detection solutions, including over 750 radiochemicals and instrumentation such as the Tri-Carb® and [removed: Quantulus™] [added: Quantulus®] GCT families of liquid scintillation analyzers, [removed: Wizard2®] [added: Wizard2TM] Gamma counters and [removed: MicroBeta2®] [added: MicroBeta2TM] plate based [removed: LSA, which] [added: LSA] are used for beta, gamma and luminescence counting in microplate and vial formats utilized in research, environmental and drug discovery applications.

[removed: - The] [added: ◦The] Opera Phenix® Plus high-content screening [removed: system, which is used] [added: system] for sensitive and high-speed phenotypic drug screening of complex cellular models.

[removed: - The] [added: ◦The] Operetta® CLS™ high-content analysis [removed: system, which] [added: system] enables scientists to reveal fine sub-cellular details from everyday assays as well as more complex studies, for example using live cells, 3D and stem cells.

[removed: - Reagents] [added: ◦Reagents] and solutions for microscopy and imaging applications.

These include [removed: PhenoVue™] [added: PhenoVue®] cellular imaging reagents and cell painting kits, PhenoPlate (formerly CellCarrier Ultra™) cellular imaging microplates and [removed: GrowDex®] [added: GrowDexTM] hydrogels, fluorophore-conjugated and enzyme-conjugated antibodies, as well as buffers and solutions, such as our Ce3D™ collection of buffers for 3D tissue imaging.

[removed: - The] [added: ◦The] Signals Image Artist™ next-generation image analysis and management platform for drug discovery research, to help scientists process and analyze high-content screening (HCS) and cellular imaging data in a matter of hours versus days or weeks, so they can make more informed decisions faster.

[removed: - The] [added: ◦The] VICTOR [removed: Nivo®] [added: NivoTM] multimode plate reader benchtop [removed: system, which is] [added: system] designed for assay development and academic labs, including those using HTRF® and AlphaLISA® assay technologies.

[removed: - The EnVision®] [added: ◦The EnVisionTM] multimode plate [removed: reader, which is] [added: reader] designed for high-throughput screening laboratories, including those using HTRF®, AlphaScreen® and AlphaLISA® assay technologies.

[removed: - A] [added: ◦A] wide range of homogeneous biochemical and cell-based reagents using HTRF®, LANCE® Ultra™, DELFIA®, AlphaLISA®, [removed: AlphaLISA ®] [added: AlphaLISA®] SureFire® [removed: Ultra,] [added: Ultra™,] AlphaScreen®, AlphaPlex® and luminescence assay [removed: technologies.][added: technologies that can be paired with our microplates, which cover a variety of applications.]

[removed: - A] [added: ◦A] broad portfolio of recombinant GPCR and ion channel cell lines, including over 300 products and 120 ready-to-use frozen cell lines for a wide range of disease areas.

[removed: - BioLegend®] [added: ◦BioLegend®] ELISA MAX™ Standard Sets, ELISA MAX™ Deluxe Sets, LEGEND MAX™ ELISA [removed: Kits] [added: Kits,] and RAPID MAX™ ELISA Kits as well as complementary solutions and buffers for immunoassays to cover more than 200 targets for human, mouse, and rat samples, many of which are designed to assess the immune environment and its inflammatory state for vaccine, infectious disease and autoimmune disease research.

[removed: - BioLegend®] [added: ◦BioLegend®] LEGENDplex™ bead-based reagents, which, in contrast to single analyte assays such as enzyme-linked immunosorbent assays (“ELISAs”), can quantitate up to 14 [removed: targets,] [added: targets] from one small sample volume [removed: in a] [added: and read on common] flow [removed: cytometry assay,] [added: cytometers,] and include both desktop and cloud-based analysis software.

[removed: - In] [added: ◦In] vivo [added: optical] imaging [removed: technologies] [added: platforms] and reagents for preclinical research, comprised of the IVIS® Spectrum™ series for 2D and 3D optical imaging and optionally integrated low-dose CT imaging and the IVIS® Lumina™ series for benchtop 2D imaging, along with [removed: IVISbrite™] [added: IVISbrite®] bioluminescent and [removed: IVISense™] [added: IVISense®] fluorescent imaging [removed: agents, cell lines] [added: agents] and [removed: dyes.][added: imaging reagents.]

[removed: - The] [added: ◦The] QuantumTM [removed: GX2] [added: GX3] system, which enables low-dose in vivo CT imaging of multiple species and areas of anatomical interest across multiple disease areas by way of high-resolution, tomographic imaging.

[removed: - GoInVivo™] [added: ◦GoInVivo™] as well as Ultra-LEAF™ and LEAF™ functional [removed: antibodies, which] [added: antibodies] provide an affordable solution for researchers performing in vivo and ex vivo studies.

[removed: - Nexcelom BioScience] [added: ◦The] high-throughput, microwell Celigo® image cytometry system, [removed: Cellaca™] [added: the Cellaca®] MX high-throughput cell counter, the [removed: new Cellaca™] [added: Cellaca®] PLX image cytometry system, and [added: the] Cellometer® automated cell counters, complemented by consumables and reagents, including reagents and kits for cell counting assays and cell viability, microplates, slides, and counting beads.

[removed: - Mimix Reference Standards, which] [added: ◦MimixTM reference standards] are cell line-derived [added: to mimic patient samples] and suitable for [removed: Next Generation Sequencing,] [added: next generation sequencing,] droplet-digital and [removed: Real-Time] [added: real-time] PCR as well as Sanger sequencing.

The platform is agnostic for seamless integration into [removed: any] quality control [removed: workflow.][added: workflows.]

[removed: - Dharmacon™ Reagents] [added: ◦Dharmacon® reagents] and gene modulation technologies such as RNAi that support drug discovery and development for greater understanding of gene function, [removed: identify] [added: identifying] genetic drivers behind human disease, [removed: develop] [added: developing] and [removed: validate] [added: validating] diagnostic workflows, and [removed: help] [added: helping] deliver biotherapeutics, cellular and gene therapies for precision medicine with a portfolio of cell engineering tools.

[removed: -] [added: ◦The] Pin-point™ base editing [removed: platform, which] [added: platform] is a CRISPR-Cas9-based technology that allows researchers to make precision base changes in genomic DNA.

[removed: - CHOSOURCE™ platform, which] [added: ◦CHOSOURCE™ platform] was expanded to include [added: a] CHO-K1 ADCC+ expression cell line for development of therapeutic antibodies in oncology, infectious disease and autoimmune conditions.

[removed: - BioLegend®’s] [added: ◦BioLegend’s] catalog of more than [removed: 20,000] [added: 33,000] SKUs, incorporating antibodies and a large collection of antibody conjugates and modifications as well as recombinant proteins, [removed: immunoassays] [added: immunoassays,] and other supportive reagents and solutions for cell and molecular analysis.

[removed: - Sirion Biotech consultancy] [added: ◦Gene Delivery] services and technologies to design and manufacture viral vectors for cell and gene therapy research and preclinical development.

[removed: - BioLegend®] [added: ◦BioLegend®] best-in-class antibodies, recombinant [removed: proteins] [added: proteins,] and related [removed: reagents, which] [added: reagents] are used across multiple applications and research areas, including proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.

[removed: - Fluorophore-conjugated antibodies, which] [added: ◦Fluorophore-conjugated antibodies] are used in flow cytometers to characterize protein expression on the surface and in internal compartments of cells.

Notable products are Brilliant Violet™ and the [removed: Spark™] [added: Spark] and [removed: Fire] [added: FireTM] dye series, among others.

[removed: - BioLegend®] [added: ◦BioLegend®] TotalSeq™ [removed: reagents, which] [added: reagents] are oligonucleotide-barcoded antibodies that enable protein detection [removed: by sequencing that can] [added: to] be combined with traditional RNA or DNA sequencing experiments with high-parameter protein [removed: detection, including comprehensive cloud-based analysis software.][added: detection.]

[removed: - Cell] [added: ◦Cell] culture and biofunctional assay reagents, including bioactive recombinant proteins, as well as other specialized reagents such as Cell-Vive™ T-NK Xeno-Free Serum Substitute (compliant with Good Manufacturing Practice requirements (“GMP”)), and other GMP-produced recombinant proteins and reagents.

[removed: - BioLegend®’s] [added: ◦BioLegend®’s] MojoSort™ [removed: and Lymphopure™ reagents] for cell separation that [removed: complement] [added: complements] our fluorophore-antibody conjugates, used for FACS (Fluorescence-activated Cell Sorting), thus covering most cell separation and cell sorting technologies and applications.

[removed: - Flex-T™] [added: ◦Flex-T™] reagents that utilize peptide-loaded major histocompatibility molecules assembled into tetramers for the identification of antigen-specific T cells.

Our Flex-T products can be used to screen the efficacy of antigen peptides for vaccine and drug trials, as well as characterize the dominance of cancer-specific self-peptides, and more recently, [removed: SARS-CoV2] [added: SARS-CoV-2] peptides for COVID-19 research.

[removed: A large collection of validated antibodies,] [added: ◦Antibodies and solutions for Western blotting,] as well as supporting buffers and substrates, [removed: which] provide a convenient set of tools to characterize protein size and relative expression levels in cell or tissue lysates.

[removed: - Signals] [added: ◦Signals] Research [removed: Platform, which] [added: platform] equips pharmaceutical scientists with the essential tools to gather, search, mine, analyze and visualize critical data, yielding actionable insights in an automated, predictive, and scalable manner.

Within life science research and development and clinical research applications, our software accelerates innovation, development, collaboration and research, ultimately leading to [added: accelerated] life-enhancing medical [removed: breakthroughs more quickly,] [added: breakthroughs,] promoting our vision of a healthier humankind.

[removed: In addition, it also] empowers scientists and formulators in specialty chemical and food sciences to analyze food, and additives, and create high-performing materials that align with sustainability initiatives, promoting energy efficiency, lower toxicity and a circular economy.

[removed: -] [added: ◦The] Signals [removed: Notebook, a] [added: NotebookTM] secure cloud-native electronic lab notebook (ELN) for chemistry, biology, research, and formulations.

From increased collaboration to securely accessible data, [added: the] Signals [removed: Notebooks] [added: NotebookTM offering] accelerates research and development workflows, increases collaboration, integrates with Microsoft Office and more.

[removed: - Signals ChemDraw®, which since 1985 has provided] [added: ◦Signals ChemDraw® software providing] solutions with powerful capabilities and integrations to help quickly turn ideas and drawings into [removed: publications.][added: publications since 1985.]

- Reagents

Data can be analyzed with their complimentary and comprehensive cloud-based Multiomics Analysis Software.

New options were created for intracellular target staining and protein-only analysis.

- Instruments

◦The EnVision NexusTM multimode plate reader, our next generation system for high-throughput screening with advanced detection technologies for Alpha, TRF, and Luminescence.

This innovative in vivo ultrasound system removes the challenges associated with conventional hand-held systems through the use of automated transducers located under the imaging stage and is easy to use, requires minimal training and produces more consistent results.

It is complemented by GoInVivo™ as well as Ultra-LEAF™ and LEAF™ functional antibodies providing an affordable solution for researchers performing in vivo and ex vivo studies.

- Software

In addition, it also

- Technology and Licensing

This includes LentiBOOST® transduction enhancer technology for improved lentiviral transduction efficiency, helping to reduce the cost of goods for cell therapies.

◦Preclinical services for oncology, leveraging capabilities such as cell panel screening, cell line engineering, functional genomic screening, and immune cell screening, for a range of applications to help accelerate the drug development process.

- Reagents

◦Biolegend launched new dyes to expand flow cytometry panel building options, including PE/Fire™ 744, Spark PLUS UV395™, Spark PLUS™ B550 antibody conjugates and Zombie UV387™ for dead cell analysis.

In addition, the Flexi-Fluor™ portfolio of reagents was created as a made-to-order, rapid alternative to traditional custom products.

◦Oligo-conjugated antibodies for intracellular detection of proteins and cytokines introduced in BioLegend's TotalSeqTM portfolio.

BioLegend also introduced a solution for high-throughput, high-parameter single-cell protein analysis - TotalSeq™ PhenoCyteTM.

PhenoCyteTM provides a streamlined, instrument-free workflow for scalable single-cell immunoprofiling.

- Instruments

◦The Cellometer™ Ascend™ automated cell counter accelerates lab workflow by mitigating human error, all while providing a consistent, standardized cell count.

Incorporated with its user-friendly Matrix software, this product performs an automated and sophisticated image analysis workflow that delivers reliable results in seconds.

- Software

◦Phenologic.AI™ software, a module in our Harmony™ high-content imaging and analysis software and in our Signals Image Artist™ image analysis and data management platform uses a pre-trained deep-learning image-analysis model to enable analysis of brightfield images and provides an additional channel for multiplexing and easier analysis of live cell assays.

- Reproductive Health

◦Utilizing next-generation sequencing, Revvity Omics labs provide testing solutions including but not limited to whole genome sequencing, whole exome sequencing, curated and customized gene panels.

This test also provides additional findings like pharmacogenomic analysis and carrier status among others.

◦Ultrarapid Whole Genome Sequencing test, a variant of the whole genome sequencing (WGS) analysis, bundles the StepOne biochemical profile, cCMV analysis and metagenomic analysis with the standard WGS analysis to help babies in the NICU with a result as fast as five days.

◦Using WGS as a backbone, Revvity Omics provides two unique products, the CNGnome® NGS Array and WholePanel ™ test.

Utilizing the uniform coverage across genome, the CNGnome NGS array is used to detect copy number events over 25kb in size, making this as a new gold standard in CNV detection.

The WholePanel test provides enhanced coverage including the intronic regions for the expertly curated WholeCancer, WholeAtaxia, WholeCardiology and WholeMuscularDystrophy gene panels.

- Applied Genomics

◦NEXTFLEX® library prep kits simplify library prep with optimized protocols and reagents, making the library preparation process more efficient and reliable.

- Immunodiagnostics

◦The chemagic™ 360 instrument is a flexible solution for automated nucleic acid isolation from 0.1-18 ml sample volumes of diverse sample materials.

The chemagic™ 360-D instrument (IVDR) and chemagic™

◦A comprehensive portfolio of chemiluminescence immunoassays and ELISAs for endocrinology testing.

◦EUROPattern ClassifierTM 2.4 AI-enhanced software module of EUROLabOfficeTM4.0 offers automated result proposals from images captured with the all-in-one IFA instrument UNIQO 160 as well as from the automated microscopes EUROPattern and EUROPattern Microscope Live.

- Reproductive Health

◦CD34+ hematopoietic stem cells from human umbilical cord blood (for research use only and not for use in diagnostic procedures).

◦The NEXTFLEX® Neo NGS RUO Panel 1 kit, which is part of a new end-to-end workflow solution for newborn sequencing research.

Effective as of April 26, 2023, we changed our name from PerkinElmer, Inc. to Revvity, Inc. Effective as of May 16, 2023, we changed the ticker symbol for our common stock to “RVTY” and the ticker symbol for our 1.875% Notes due 2026 to “RVTY 26”.

Recent Developments

As part of our strategy to grow our core businesses and transform our portfolio, we have recently taken the following actions:

*Discontinued Operations in Fiscal Year 2023:*

On March 13, 2023, we completed the previously announced sale (the “Closing”) of certain assets and the equity interests of certain entities constituting our Applied, Food and Enterprise Services businesses (the “Business”) to PerkinElmer Topco, L.P. (formerly known as Polaris Purchaser, L.P.) (the “Purchaser”), a Delaware limited partnership owned by funds managed by affiliates of New Mountain Capital L.L.C. (the “Sponsor”), for an aggregate purchase price of up to $2.45 billion.

We received approximately $2.13 billion in cash proceeds, before transaction costs and subject to post-closing adjustments.

We are entitled to an additional $75.0 million in proceeds as consideration for our ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the Purchaser.

This consideration is expected to be received in installments through the first half of 2025.

In addition, we are entitled to additional consideration of up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive on a sale or other capital events related to the Business.

- The MuviCyte™ live-cell imaging system, designed to operate inside a cell-culture incubator, enabling researchers to study cellular behaviors and pathways in living cells to gain a deeper understanding of functions, disease mechanisms and responses to treatments.

- The EnSight® multimode plate reader benchtop system, which offers well plate imaging alongside labeled detection technologies for target-based and phenotypic assays.

- The T-SPOT® Discovery SARS-CoV-2 research-use-only assay to investigate cell-mediated immunity related to COVID-19.

- Antibodies and solutions for Western blotting.

Originally launched in North America in 2022, it is now globally available.

- Pin-pointTM base editing reagents, which improve access to new-generation editing technology.

The launch of these reagents puts clinically relevant base editing using the Pin-point platform in the hands of preclinical laboratories seeking to accelerate genomic insights and cell therapy research.

- IVIS® Spectrum 2 and IVIS SpectrumCT 2 next-generation imaging systems, our newest flagship platforms setting the standard in high-throughput performance and versatility.

- QuantumTM GX3 microCT imaging solution, a high-throughput system with superior spatial resolution and fast, low-dose scanning for diverse *in vivo* and biological *ex vivo* applications.

With class-leading resolution, the system is designed for a wide applications, including bone imaging.

- Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across research and development disciplines from drug discovery to specialty chemicals material development.

- HIVE CLX ™ scRNAseq Solution, which integrates sample storage and single cell profiling into a complete workflow, solving the issues that limit single cell RNA analysis.

- ELISAs covering endocrinology, autoimmunity, diabetes monitoring, steroids, thyroid monitoring, animal research and tumor markers.

- Pre-NAT II, which provides fully automated high-throughput sample preparation for molecular genetic diagnostics, consisting of nucleic acid extraction and subsequent pipetting of the PCRs.

- Prenatal and postnatal testing utilizing Revvity Omics Next Generation Sequencing products including gene panels, exomes and genomes.

- Revvity Omics test for Facioscapularhumeral dystrophy (FSHD) using Genome Optical Mapping technology.

- Revvity Omics WholePanel test, which is an enhanced panel testing (WholeCancer, WholeAtaxia, WholeCardiology and WholeMuscularDystrophy panels) using genome sequencing as a backbone and provides full intronic coverage and short tandem repeat screening in one test.

- Revvity Omics UltraRapid Whole Genome Sequencing with StepOne, CMV detection and metagenomic analysis, which provides the sickest babies in NICUs with multiomic testing results in five days or less.

- 89 new IIFT for the ultrafast automated microscope “EUROPattern Microscope Live”.

- Anti-TBE Virus ELISA 2.0 (IgG) and Anti-TBE Virus CSF ELISA 2.0 (IgG) for detection of IgG antibodies against TBE virus in serum and CSF, respectively (CE-marked, IVDR-compliant).

We generally have multi-year

international and United States federal, state and local laws and regulations.

*Diversity and Inclusion*

We believe in an inclusive workforce, where employees from a number of cultures and countries are engaged and encouraged to leverage their collective talents.

As of the date of filing of this annual report on Form 10-K, women comprised roughly 40% of our leadership positions on a global basis, which we define as director level and above.

We have provided further information regarding our diversity demographics in our Environmental, Social, and Governance (ESG) Report and elsewhere on our website at esg.revvity.com, including summarized data from our EEO-1 form.

It helps our employees and stakeholders know and understand of our commitment to make positive impacts on our employees, customers, local communities and the environment, while engaging others in our efforts.

Our EEO-1 form is a report filed with the United States Equal Employment Opportunity Commission describing the racial, ethnic and gender composition of our U.S.-based workforce.

Information on our website, including the ESG Report, shall not be deemed incorporated by reference into this annual report.

By maintaining a culture of diversity and inclusion, we believe that we can innovate more effectively.

To that end, we seek to promote diverse perspectives throughout our organization and are an equal opportunity employer committed to making employment decisions without regard to race, religion, national or ethnic origin, sex, sexual orientation, gender identity or expression, age, disability, protected veteran status or other characteristics protected by law.

Although we have established accruals for potential losses that we believe are probable and reasonably estimable, in the opinion of our management, based on its review of the information available at this time, the total cost of resolving these contingencies at December [removed: 31, 2023] [added: 29, 2024] should not have a material adverse effect on our consolidated financial statements included in this annual report on Form 10-K.

| | | | For the fiscal year ended December [removed: 31, 2023] [added: 29, 2024] | | |

The aggregate market value of the common stock, $1 par value per share, held by non-affiliates of the registrant on June [removed: 30, 2023,] [added: 28, 2024,] the last business day of the registrant’s most recently completed second fiscal quarter, was [removed: $14,697,780,722] [added: $12,871,238,120] based upon the last reported sale of [removed: $118.79] [added: $104.86] per share of common stock on June [removed: 30, 2023.][added: 28, 2024.]

As of February [removed: 23, 2024,] [added: 21, 2025,] there were outstanding [removed: 123,529,821] [added: 120,187,286] shares of common stock, $1 par value per share.

Portions of Revvity, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on April [removed: 23, 2024] [added: 22, 2025] are incorporated by reference into Part III of this Form 10-K.

| Item 1. | | | [removed: [Business](#i811ab3117c4643edb9bdbfe1493fde34_13)] [added: [Business](#i9b5569a8d050455c84db11039ac6a928_13)] | | | [removed: [3](#i811ab3117c4643edb9bdbfe1493fde34_13)] [added: [3](#i9b5569a8d050455c84db11039ac6a928_13)] | | |

| Item 1A. | | | [Risk [removed: Factors](#i811ab3117c4643edb9bdbfe1493fde34_16)] [added: Factors](#i9b5569a8d050455c84db11039ac6a928_16)] | | | [removed: [13](#i811ab3117c4643edb9bdbfe1493fde34_16)] [added: [13](#i9b5569a8d050455c84db11039ac6a928_16)] | | |

| Item 1B. | | | [Unresolved Staff [removed: Comments](#i811ab3117c4643edb9bdbfe1493fde34_19)] [added: Comments](#i9b5569a8d050455c84db11039ac6a928_19)] | | | [removed: [21](#i811ab3117c4643edb9bdbfe1493fde34_19)] [added: [21](#i9b5569a8d050455c84db11039ac6a928_19)] | | |

| Item 1C. | | | [Cybersecurity [removed: Disclosures](#i811ab3117c4643edb9bdbfe1493fde34_1892)] [added: Disclosures](#i9b5569a8d050455c84db11039ac6a928_22)] | | | [removed: [21](#i811ab3117c4643edb9bdbfe1493fde34_1892)] [added: [22](#i9b5569a8d050455c84db11039ac6a928_22)] | | |

| Item 2. | | | [removed: [Properties](#i811ab3117c4643edb9bdbfe1493fde34_22)] [added: [Properties](#i9b5569a8d050455c84db11039ac6a928_25)] | | | [removed: [22](#i811ab3117c4643edb9bdbfe1493fde34_22)] [added: [22](#i9b5569a8d050455c84db11039ac6a928_25)] | | |

| Item 3. | | | [Legal [removed: Proceedings](#i811ab3117c4643edb9bdbfe1493fde34_25)] [added: Proceedings](#i9b5569a8d050455c84db11039ac6a928_28)] | | | [removed: [22](#i811ab3117c4643edb9bdbfe1493fde34_25)] [added: [23](#i9b5569a8d050455c84db11039ac6a928_28)] | | |

| Item 4. | | | [Mine Safety [removed: Disclosures](#i811ab3117c4643edb9bdbfe1493fde34_28)] [added: Disclosures](#i9b5569a8d050455c84db11039ac6a928_31)] | | | [removed: [22](#i811ab3117c4643edb9bdbfe1493fde34_28)] [added: [23](#i9b5569a8d050455c84db11039ac6a928_31)] | | |

| Item 5. | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i811ab3117c4643edb9bdbfe1493fde34_37)] [added: Securities](#i9b5569a8d050455c84db11039ac6a928_40)] | | | [removed: [25](#i811ab3117c4643edb9bdbfe1493fde34_37)] [added: [26](#i9b5569a8d050455c84db11039ac6a928_40)] | | |

| Item 6. | | | [removed: [\[Reserved\]](#i811ab3117c4643edb9bdbfe1493fde34_40)] [added: [\[Reserved\]](#i9b5569a8d050455c84db11039ac6a928_43)] | | | [removed: [26](#i811ab3117c4643edb9bdbfe1493fde34_40)] [added: [27](#i9b5569a8d050455c84db11039ac6a928_43)] | | |

| Item 7. | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i811ab3117c4643edb9bdbfe1493fde34_46)] [added: Operations](#i9b5569a8d050455c84db11039ac6a928_49)] | | | [removed: [27](#i811ab3117c4643edb9bdbfe1493fde34_46)] [added: [28](#i9b5569a8d050455c84db11039ac6a928_49)] | | |

| Item 7A. | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#i811ab3117c4643edb9bdbfe1493fde34_55)] [added: Risk](#i9b5569a8d050455c84db11039ac6a928_58)] | | | [removed: [37](#i811ab3117c4643edb9bdbfe1493fde34_55)] [added: [36](#i9b5569a8d050455c84db11039ac6a928_58)] | | |

| Item 8. | | | [Financial Statements and Supplementary [removed: Data](#i811ab3117c4643edb9bdbfe1493fde34_58)] [added: Data](#i9b5569a8d050455c84db11039ac6a928_61)] | | | [removed: [39](#i811ab3117c4643edb9bdbfe1493fde34_58)] [added: [38](#i9b5569a8d050455c84db11039ac6a928_61)] | | |

| Item 9. | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i811ab3117c4643edb9bdbfe1493fde34_190)] [added: Disclosure](#i9b5569a8d050455c84db11039ac6a928_193)] | | | [removed: [81](#i811ab3117c4643edb9bdbfe1493fde34_190)] [added: [78](#i9b5569a8d050455c84db11039ac6a928_193)] | | |

| Item 9A. | | | [Controls and [removed: Procedures](#i811ab3117c4643edb9bdbfe1493fde34_193)] [added: Procedures](#i9b5569a8d050455c84db11039ac6a928_196)] | | | [removed: [81](#i811ab3117c4643edb9bdbfe1493fde34_193)] [added: [78](#i9b5569a8d050455c84db11039ac6a928_196)] | | |

| Item 9B. | | | [Other [removed: Information](#i811ab3117c4643edb9bdbfe1493fde34_196)] [added: Information](#i9b5569a8d050455c84db11039ac6a928_199)] | | | [removed: [84](#i811ab3117c4643edb9bdbfe1493fde34_196)] [added: [81](#i9b5569a8d050455c84db11039ac6a928_199)] | | |

| Item 9C. | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i811ab3117c4643edb9bdbfe1493fde34_199)] [added: Inspections](#i9b5569a8d050455c84db11039ac6a928_202)] | | | [removed: [84](#i811ab3117c4643edb9bdbfe1493fde34_199)] [added: [81](#i9b5569a8d050455c84db11039ac6a928_202)] | | |

| Item 10. | | | [Directors, Executive Officers and Corporate [removed: Governance](#i811ab3117c4643edb9bdbfe1493fde34_205)] [added: Governance](#i9b5569a8d050455c84db11039ac6a928_208)] | | | [removed: [85](#i811ab3117c4643edb9bdbfe1493fde34_205)] [added: [82](#i9b5569a8d050455c84db11039ac6a928_208)] | | |

| Item 11. | | | [Executive [removed: Compensation](#i811ab3117c4643edb9bdbfe1493fde34_208)] [added: Compensation](#i9b5569a8d050455c84db11039ac6a928_211)] | | | [removed: [85](#i811ab3117c4643edb9bdbfe1493fde34_208)] [added: [82](#i9b5569a8d050455c84db11039ac6a928_211)] | | |

| Item 12. | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i811ab3117c4643edb9bdbfe1493fde34_211)] [added: Matters](#i9b5569a8d050455c84db11039ac6a928_214)] | | | [removed: [85](#i811ab3117c4643edb9bdbfe1493fde34_211)] [added: [82](#i9b5569a8d050455c84db11039ac6a928_214)] | | |

| Item 13. | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i811ab3117c4643edb9bdbfe1493fde34_214)] [added: Independence](#i9b5569a8d050455c84db11039ac6a928_217)] | | | [removed: [85](#i811ab3117c4643edb9bdbfe1493fde34_214)] [added: [82](#i9b5569a8d050455c84db11039ac6a928_217)] | | |

| Item 14. | | | [Principal Accountant Fees and [removed: Services](#i811ab3117c4643edb9bdbfe1493fde34_217)] [added: Services](#i9b5569a8d050455c84db11039ac6a928_220)] | | | [removed: [85](#i811ab3117c4643edb9bdbfe1493fde34_217)] [added: [82](#i9b5569a8d050455c84db11039ac6a928_220)] | | |

| Item 15. | | | [Exhibits and Financial Statement [removed: Schedules](#i811ab3117c4643edb9bdbfe1493fde34_223)] [added: Schedules](#i9b5569a8d050455c84db11039ac6a928_226)] | | | [removed: [86](#i811ab3117c4643edb9bdbfe1493fde34_223)] [added: [83](#i9b5569a8d050455c84db11039ac6a928_226)] | | |

| Item 16. | | | [Form 10-K [removed: Summary](#i811ab3117c4643edb9bdbfe1493fde34_226)] [added: Summary](#i9b5569a8d050455c84db11039ac6a928_229)] | | | [removed: [91](#i811ab3117c4643edb9bdbfe1493fde34_226)] [added: [88](#i9b5569a8d050455c84db11039ac6a928_229)] | | |

| 77 4th Avenue | | | Waltham, | | | Massachusetts | | | | | | 02451 | | |

| [Signatures](#i9b5569a8d050455c84db11039ac6a928_232) | | | | | | [88](#i9b5569a8d050455c84db11039ac6a928_232) | | |

| 940 Winter Street, | | | Waltham, | | | Massachusetts | | | | | | 02451 | | |

| [Signatures](#i811ab3117c4643edb9bdbfe1493fde34_229) | | | | | | [91](#i811ab3117c4643edb9bdbfe1493fde34_229) | | |

[removed: The Company’s] [added: Our] Chief Information Officer is responsible for developing and implementing our information security program.

We have implemented comprehensive cybersecurity initiatives for our employees, including education, training, and testing.

These measures are conducted annually to ensure our employees remain up-to-date with the latest security practices, complementing our continuously improving processes and systems.

This team leverages internal IT resources, a managed security service provider, and additional third-party security software and technology services.

See Note [removed: 21,] [added: 20,] *Leases,* in the Notes to Consolidated Financial Statements for further discussion of our leases.

Listed below are our executive officers as of February [removed: 27, 2024.][added: 25, 2025.]

| Prahlad Singh | | | | | | President and Chief Executive Officer | | | | | | [removed: 59] [added: 60] | | |

| Maxwell Krakowiak | | | | | | Senior Vice President and Chief Financial Officer | | | | | | [removed: 34] [added: 35] | | |

| Joel S. Goldberg | | | | | | Senior Vice President, Administration, General Counsel and Secretary | | | | | | [removed: 55] [added: 56] | | |

| Miriame Victor | | | | | | Senior Vice President, Chief Commercial Officer | | | | | | [removed: 43] [added: 44] | | |

| Tajinder Vohra | | | | | | Senior Vice President, Global Operations | | | | | | [removed: 58] [added: 59] | | |

| Anita Gonzales | | | | | | Vice President, Controller | | | | | | [removed: 48] [added: 49] | | |

*Prahlad Singh, [removed: 59*.][added: 60*.]

*Maxwell Krakowiak, [removed: 34*.][added: 35*.]

Goldberg*, [removed: *55*.][added: *56*.]

*Miriame Victor, [removed: 43*.][added: 44*.]

[added: In that role, she oversees Revvity’s product commercialization efforts across all] businesses, having previously completed the successful consolidation of the Diagnostics business with other businesses into one unified commercial organization.

*Tajinder Vohra, [removed: 58*.][added: 59*.]

*Anita Gonzales, [removed: 48.*] [added: 49.*] Mrs. Gonzales was appointed our Vice President and Controller in May 2023, having joined Revvity as Senior Director of Integration and Controllership Initiatives in March 2021.

| Daniel R. Tereau | | | | | | Senior Vice President, Strategy and Business Development | | | | | | 57 | | |

*Daniel R.

Tereau, 57.* Mr. Tereau was appointed Senior Vice President, Strategy and Business Development in January 2016, having joined Revvity in April 2014 as Vice President, Strategy and Business Development.

He is responsible for leading Revvity’s overall strategic planning and business development activities.

Prior to joining Revvity, Mr. Tereau served on Novartis’ leadership team as Senior Vice President and Global Head of Strategy, Business Development and Licensing, where he was responsible for global strategy and business development for the Consumer Health division.

Earlier in his career, Mr. Tereau held similar roles at Thermo Fisher Scientific and GE Healthcare.

Mr. Tereau holds a Bachelor of Science degree in finance from Ferris State University, a Juris Doctorate from Wayne State University, and earned his Master of Business Administration from Yale University.

In that role, she oversees Revvity’s product commercialization efforts across all

As of February [removed: 23, 2024,] [added: 21, 2025,] we had approximately [removed: 2,923] [added: 2,753] holders of record of our common stock.

Stock [removed: Repurchases][added: Repurchases and Dividends]

During the fourth quarter of fiscal year [removed: 2023,] [added: 2024,] we repurchased [removed: 45,905] [added: 37,443] shares of common stock for this purpose at an aggregate cost of [removed: $4.9] [added: $4.6] million.

(2)On [removed: July 22, 2022,] [added: April 27, 2023,] our Board authorized us to repurchase shares of common stock for an aggregate amount up to [removed: $300.0] [added: $600.0] million under a stock repurchase program (the “Repurchase Program”).

On [removed: April 27, 2023,] [added: October 24, 2024,] the Repurchase Program was terminated by our Board and our Board authorized us to repurchase shares of common stock for an aggregate amount up to [removed: $600.0 million] [added: $1.0 billion] under a new stock repurchase program (the “New Repurchase Program”).

The New Repurchase Program will expire on [removed: April 26, 2025,] [added: October 23, 2026,] unless terminated earlier by our Board and may be suspended or discontinued at any time.

During fiscal year [removed: 2023,] [added: 2024,] we repurchased [removed: 1,004,544] [added: 1,820,296] shares of common stock under the Repurchase Program for an aggregate cost of [removed: $131.3] [added: $213.6] million.

During the fourth quarter of fiscal year [removed: 2023, no] [added: 2024, we repurchased 1,238,755] shares of common stock [removed: were repurchased] under the New Repurchase [removed: Program.][added: Program for an aggregate cost of $142.8 million.]

During [added: the fourth quarter of] fiscal year [removed: 2023,] [added: 2024,] we repurchased [removed: 2,159,985] [added: 284,985] shares of common stock under the [removed: New] Repurchase Program for an aggregate cost of [removed: $244.6] [added: $34.3] million.

As of December [removed: 31, 2023, $355.4] [added: 29, 2024, $857.2] million remained available for aggregate repurchases of shares under the New Repurchase Program.

Set forth below is a line graph comparing the cumulative total shareholder return on our common stock against the cumulative total return of the S&P Composite-500 Index and the S&P 500 Life Sciences Tools & Services Industry Index for the five fiscal years from December [removed: 30, 2018] [added: 29, 2019] to December [removed: 31, 2023.][added: 29, 2024.]

[removed: ][added: ]

| | | | [removed: 12/30/2018] [added: 12/29/2019] | | | | | | [removed: 12/29/2019] [added: 1/3/2021] | | | | | | [removed: 1/3/2021] [added: 1/2/2022] | | | | | | [removed: 1/2/2022] [added: 1/1/2023] | | | | | | [removed: 1/1/2023] [added: 12/31/2023] | | | | | | [removed: 12/31/2023] [added: 12/29/2024] | | |

| S&P 500 Life Sciences Tools & Services Industry Index | | | $ | 100.00 | | | | | $ | [removed: 132.52] [added: 133.01] | | | | | $ | [removed: 176.28] [added: 184.53] | | | | | $ | [removed: 244.55] [added: 142.26] | | | | | $ | [removed: 188.53] [added: 137.88] | | | | | $ | [removed: 182.72] [added: 133.07] | |

| September 30, 2024 - October 27, 2024 | | | 351,461 | | | | | | $ | 120.54 | | | | | 30,000 | | | | | | $ | 996,456,502 | |

| October 28, 2024 - November 24, 2024 | | | 537,773 | | | | | | 115.16 | | | | | | 537,705 | | | | | | 934,536,467 | | |

| November 25, 2024 - December 29, 2024 | | | 671,949 | | | | | | 115.23 | | | | | | 671,050 | | | | | | 857,209,712 | | |

| Activity for quarter ended December 29, 2024 | | | 1,561,183 | | | | | | $ | 116.40 | | | | | 1,238,755 | | | | | | $ | 857,209,712 | |

Our Board of Directors declared a cash dividend of $0.07 per share during the fourth quarter of fiscal year 2024 that was paid in February 2025.

Refer to Note 17, *Stockholders' Equity,* in the Notes to Consolidated Financial Statements for further discussion regarding stock repurchases and dividends.

| Revvity, Inc. | | | $ | 100.00 | | | | | $ | 148.27 | | | | | $ | 208.13 | | | | | $ | 145.42 | | | | | $ | 113.62 | | | | | $ | 116.71 | |

| S&P 500 Index | | | $ | 100.00 | | | | | $ | 118.40 | | | | | $ | 152.39 | | | | | $ | 124.79 | | | | | $ | 157.59 | | | | | $ | 197.02 | |

| October 2, 2023 - October 29, 2023 | | | 45,723 | | | | | | $ | 107.63 | | | | | — | | | | | | $ | 355,447,934 | |

| October 30, 2023 - November 26, 2023 | | | 57 | | | | | | 87.85 | | | | | | — | | | | | | 355,447,934 | | |

| November 27, 2023 - December 31, 2023 | | | 125 | | | | | | 101.31 | | | | | | — | | | | | | 355,447,934 | | |

| Activity for quarter ended December 31, 2023 | | | 45,905 | | | | | | $ | 107.59 | | | | | — | | | | | | $ | 355,447,934 | |

| Revvity, Inc. | | | $ | 100.00 | | | | | $ | 125.96 | | | | | $ | 186.77 | | | | | $ | 262.16 | | | | | $ | 183.17 | | | | | $ | 143.12 | |

| S&P 500 Index | | | $ | 100.00 | | | | | $ | 131.49 | | | | | $ | 155.68 | | | | | $ | 200.37 | | | | | $ | 164.08 | | | | | $ | 207.21 | |

| [Report of Independent Registered Public Accounting [removed: Firm](#i811ab3117c4643edb9bdbfe1493fde34_61)] [added: Firm](#i9b5569a8d050455c84db11039ac6a928_64)] (PCAOB ID No. 34) | | | [removed: [40](#i811ab3117c4643edb9bdbfe1493fde34_61)] [added: [39](#i9b5569a8d050455c84db11039ac6a928_64)] | | |

| [Consolidated Statements of Operations for Each of the Three Fiscal Years in the Period Ended [removed: January 1, 2023](#i811ab3117c4643edb9bdbfe1493fde34_64)] [added: December 29, 2024](#i9b5569a8d050455c84db11039ac6a928_67)] | | | [removed: [41](#i811ab3117c4643edb9bdbfe1493fde34_64)] [added: [40](#i9b5569a8d050455c84db11039ac6a928_67)] | | |

| [Consolidated Statements of Comprehensive Income for Each of the Three Fiscal Years in the Period Ended [removed: January 1, 2023](#i811ab3117c4643edb9bdbfe1493fde34_67)] [added: December 29, 2024](#i9b5569a8d050455c84db11039ac6a928_70)] | | | [removed: [42](#i811ab3117c4643edb9bdbfe1493fde34_67)] [added: [41](#i9b5569a8d050455c84db11039ac6a928_70)] | | |

| [Consolidated Balance Sheets as of [removed: January 1, 2023] [added: December 29, 2024] and [removed: January 2, 2022](#i811ab3117c4643edb9bdbfe1493fde34_70)] [added: December 31, 2023](#i9b5569a8d050455c84db11039ac6a928_73)] | | | [removed: [43](#i811ab3117c4643edb9bdbfe1493fde34_70)] [added: [42](#i9b5569a8d050455c84db11039ac6a928_73)] | | |

| [Consolidated Statements of Stockholders’ Equity for Each of the Three Fiscal Years in the Period Ended [removed: January 1, 2023](#i811ab3117c4643edb9bdbfe1493fde34_76)] [added: December 29, 2024](#i9b5569a8d050455c84db11039ac6a928_79)] | | | [removed: [44](#i811ab3117c4643edb9bdbfe1493fde34_76)] [added: [43](#i9b5569a8d050455c84db11039ac6a928_79)] | | |

| [Consolidated Statements of Cash Flows for Each of the Three Fiscal Years in the Period Ended [removed: January 1, 2023](#i811ab3117c4643edb9bdbfe1493fde34_79)] [added: December 29, 2024](#i9b5569a8d050455c84db11039ac6a928_82)] | | | [removed: [45](#i811ab3117c4643edb9bdbfe1493fde34_79)] [added: [44](#i9b5569a8d050455c84db11039ac6a928_82)] | | |

| [Notes to Consolidated Financial [removed: Statements](#i811ab3117c4643edb9bdbfe1493fde34_82)] [added: Statements](#i9b5569a8d050455c84db11039ac6a928_85)] | | | [removed: [47](#i811ab3117c4643edb9bdbfe1493fde34_82)] [added: [46](#i9b5569a8d050455c84db11039ac6a928_85)] | | |

We have audited the accompanying consolidated balance sheets of Revvity, Inc. and subsidiaries (the “Company”) as of December [removed: 31, 2023] [added: 29, 2024] and [removed: January 1,] [added: December 31,] 2023, the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows, for each of the three years in the period ended December [removed: 31, 2023,] [added: 29, 2024,] and the related notes (collectively referred to as the “financial statements”).

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December [removed: 31, 2023] [added: 29, 2024] and [removed: January 1,] [added: December 31,] 2023, and the results of its operations and its cash flows for each of the three years in the period ended December [removed: 31, 2023,] [added: 29, 2024,] in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December [removed: 31, 2023,] [added: 29, 2024,] based on criteria established in *Internal Control - Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 27, 2024,] [added: 25, 2025,] expressed an unqualified opinion on the Company’s internal control over financial reporting.

[removed: Discontinued Operations — Gain on Sale] [added: Goodwill of Life Sciences Reporting Unit] — Refer to Notes [removed: 4] [added: 1] and [removed: 20] [added: 11] to the financial statements

[removed: On] [added: In] March [removed: 13,] 2023, the Company completed the [removed: previously announced] sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”).

[removed: First,] [added: At] the [added: Closing, the] Company [removed: is] [added: was] entitled to [removed: proceeds of] [added: an additional] $75.0 million [removed: as consideration for] [added: in proceeds payable in installments to commence upon] the Company’s ceasing [added: the] use of the PerkinElmer brand and related trademarks and transferring them to the [removed: purchaser (“Brand Sale”).][added: Purchaser (the “Brand Fee”).]

Our audit procedures related to the [removed: accounting treatment for the recognition] [added: forecasts] of [removed: the Brand Sale and the recognition] [added: future revenue] and [removed: measurement] [added: selection] of the [removed: Contingent Gain] [added: discount rate] included the following, among others:

| | | | December [removed: 31, 2023] [added: 29, 2024] | | | | | | [removed: January 1,] [added: December 31,] 2023 | | | | | | January [removed: 2, 2022] [added: 1, 2023] | | |

| | | | [removed: (In] [added: (In] thousands, except per share [removed: data)] [added: data)] | | | | | | | | | | | | | | |

| Product revenue | | | $ | [removed: 2,415,893] [added: 2,338,211] | | | | | $ | [removed: 2,634,582] [added: 2,415,893] | | | | | $ | [removed: 2,735,068] [added: 2,634,582] | |

| Service revenue | | | [removed: 334,678] [added: 416,815] | | | | | | [removed: 677,240] [added: 334,678] | | | | | | [removed: 1,092,740] [added: 677,240] | | |

| Total revenue | | | [removed: 2,750,571] [added: 2,755,026] | | | | | | [removed: 3,311,822] [added: 2,750,571] | | | | | | [removed: 3,827,808] [added: 3,311,822] | | |

| Cost of product revenue | | | [removed: 1,077,744] [added: 1,041,749] | | | | | | [removed: 1,150,402] [added: 1,077,744] | | | | | | [removed: 1,129,223] [added: 1,150,402] | | |

| Cost of service revenue | | | [removed: 133,136] [added: 175,618] | | | | | | [removed: 171,590] [added: 133,136] | | | | | | [removed: 264,598] [added: 171,590] | | |

| Selling, general and administrative expenses | | | [removed: 1,022,551] [added: 994,074] | | | | | | [removed: 1,025,514] [added: 1,022,551] | | | | | | [removed: 975,193] [added: 1,025,514] | | |

| Research and development expenses | | | [removed: 216,578] [added: 196,844] | | | | | | [removed: 221,617] [added: 216,578] | | | | | | [removed: 200,337] [added: 221,617] | | |

| Operating income from continuing operations | | | [removed: 300,562] [added: 346,741] | | | | | | [removed: 742,699] [added: 300,562] | | | | | | [removed: 1,258,457] [added: 742,699] | | |

| Interest and other expense, net | | | [removed: 117,586] [added: 30,615] | | | | | | [removed: 90,862] [added: 117,586] | | | | | | [removed: 54,875] [added: 90,862] | | |

| Income from continuing operations before income taxes | | | [removed: 182,976] [added: 316,126] | | | | | | [removed: 651,837] [added: 182,976] | | | | | | [removed: 1,203,582] [added: 651,837] | | |

| Provision for income taxes | | | [removed: 3,473] [added: 33,055] | | | | | | [removed: 139,161] [added: 3,473] | | | | | | [removed: 314,146] [added: 139,161] | | |

| Income from continuing operations | | | [removed: 179,503] [added: 283,071] | | | | | | [removed: 512,676] [added: 179,503] | | | | | | [removed: 889,436] [added: 512,676] | | |

| [removed: Income] [added: (Loss) income] from discontinued operations | | | [removed: 513,591] [added: (12,686)] | | | | | | [removed: 56,503] [added: 513,591] | | | | | | [removed: 53,721] [added: 56,503] | | |

| Net income | | | $ | [removed: 693,094] [added: 270,385] | | | | | $ | [removed: 569,179] [added: 693,094] | | | | | $ | [removed: 943,157] [added: 569,179] | |

| Income from continuing operations | | | $ | [removed: 1.44] [added: 2.31] | | | | | $ | [removed: 4.06] [added: 1.44] | | | | | $ | [removed: 7.66] [added: 4.06] | |

| [removed: Income] [added: (Loss) income] from discontinued operations | | | [removed: 4.12] [added: (0.10)] | | | | | | [removed: 0.45] [added: 4.12] | | | | | | [removed: 0.46] [added: 0.45] | | |

| Net income | | | $ | [removed: 5.56] [added: 2.21] | | | | | $ | [removed: 4.51] [added: 5.56] | | | | | $ | [removed: 8.12] [added: 4.51] | |

| Income from continuing operations | | | $ | [removed: 1.44] [added: 2.30] | | | | | $ | [removed: 4.06] [added: 1.44] | | | | | $ | [removed: 7.62] [added: 4.06] | |

| [removed: Income] [added: (Loss) income] from discontinued operations | | | [removed: 4.11] [added: (0.10)] | | | | | | [removed: 0.45] [added: 4.11] | | | | | | [removed: 0.46] [added: 0.45] | | |

| Net income | | | $ | [removed: 5.55] [added: 2.20] | | | | | $ | [removed: 4.50] [added: 5.55] | | | | | $ | [removed: 8.08] [added: 4.50] | |

| | | | December [removed: 31, 2023] [added: 29, 2024] | | | | | | [removed: January 1,] [added: December 31,] 2023 | | | | | | January [removed: 2, 2022] [added: 1, 2023] | | |

| | | | [removed: (In thousands)] [added: (In thousands)] | | | | | | | | | | | | | | |

| Net income | | | $ | [removed: 693,094] [added: 270,385] | | | | | $ | [removed: 569,179] [added: 693,094] | | | | | $ | [removed: 943,157] [added: 569,179] | |

| Other comprehensive [removed: income] (loss) [added: income] | | | | | | | | | | | | | | | | | |

As of December 29, 2024, the Company’s balance of goodwill was $6.5 billion, of which $4.3 billion was allocated to the Life Sciences reporting unit.

In connection with the annual impairment assessment as of November 1, 2024, the Company concluded that the fair value of each reporting unit exceeded the carrying value of each reporting unit and no impairment was recognized.

The fair value of the Life Sciences reporting unit exceeded the carrying value by more than 10% but less than 20%.

The Company determined the fair value of the Life Sciences reporting unit using a combination of an income approach and a discounted cash flow model.

The discounted cash flow model required management to make significant estimates and assumptions related to the discount

rate and forecasts of future revenue.

Changes in these assumptions could have a significant impact on the fair value of the reporting unit.

We identified the valuation of the Life Sciences reporting unit as a critical audit matter because of the significant estimates and assumptions management made to measure the fair value of the Life Sciences reporting unit.

These fair value measurements required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists, when performing audit procedures to evaluate the reasonableness of management’s forecasts of future revenue and the selection of the discount rate for the Life Sciences reporting unit.

–We tested the effectiveness of controls over management’s goodwill impairment evaluation, including those controls related to management’s forecasts and selection of the discount rate used in measuring the fair value of the Life Sciences reporting unit.

–We evaluated management’s ability to accurately forecast operating results by comparing actual results to management’s historical forecasts.

–We evaluated the reasonableness of management’s forecasts by comparing the forecasts to (1) historical results, (2) internal communications, budgets and other information obtained while performing the audit and (3) external information.

–With the assistance of our fair value specialists, we performed the following:

–We evaluated the discount rate, including testing the underlying source information and developing a range of independent estimates and comparing those to the discount rate selected by management.

–We tested the mathematical accuracy of the calculations.

February 25, 2025

| Dividends ($0.28 per common share, see Note 17) | | | — | | | | | | — | | | | | | — | | | | | | (35,335) | | | | | | — | | | | | | (35,335) | | |

| Dividends ($0.28 per common share, see Note 17) | | | — | | | | | | — | | | | | | — | | | | | | (34,900) | | | | | | — | | | | | | (34,900) | | |

| Net income | | | — | | | | | | — | | | | | | — | | | | | | 270,385 | | | | | | — | | | | | | 270,385 | | |

| Dividends ($0.28 per common share, see Note 17) | | | — | | | | | | — | | | | | | — | | | | | | (34,374) | | | | | | — | | | | | | (34,374) | | |

| Purchases of common stock | | | (3,146) | | | | | | (3,146) | | | | | | (366,222) | | | | | | — | | | | | | — | | | | | | (369,368) | | |

| Balance, December 29, 2024 | | | 120,646 | | | | | | $ | 120,646 | | | | | $ | 2,097,110 | | | | | $ | 5,845,223 | | | | | $ | (396,105) | | | | | $ | 7,666,874 | |

The Company capitalizes certain qualified costs incurred in connection with the development of internal-use software.

The Company evaluates the costs incurred during the application development stage of internal use software to determine whether the costs meet the criteria for capitalization.

Costs related to preliminary project activities and post implementation activities are expensed as incurred.

The Company changed the measurement date to more closely align the annual impairment testing date with the most current information from the budgeting and strategic planning process.

The Company believes the change in goodwill impairment testing date does not represent a material change to the Company’s method of applying an accounting principle in light of the Company’s internal controls and requirements to assess goodwill impairment upon certain triggering events.

This change was applied prospectively and

The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation.

Settled cash flow hedges related to forecasted transactions that remain probable are recorded

In November 2024, the FASB issued Accounting Standards Update 2024-03, *Disaggregation of Income Statement Expenses* (“ASU 2024-03”).

ASU 2024-03 will require public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items.

Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements.

In addition, ASU 2024-03 requires public entities to disclose selling expenses on an annual and interim basis.

The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.

The Company adopted the guidance in fiscal year 2024 and has included the additional disclosures related to the reportable segments in Note 21, *Industry Segment and Geographic Area Information.*

*Unbilled receivable and Contract assets:* The timing of revenue recognition may differ from the timing of customer billing.

When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets.

Unbilled receivables totaled $80.6 million and $75.8 million at December 29, 2024 and December 31, 2023, respectively, primarily related to the Life Sciences software business.

The Company has no material contract assets as of December 29, 2024 and December 31, 2023.

| --- | --- | --- | --- | --- | --- |

The Company received cash proceeds of $2.13 billion and is entitled to two elements of additional consideration that become payable upon the resolution of certain events.

This consideration is expected to be received in installments through the first half of 2025.

The Company is also entitled to proceeds of up to $150.0 million that is contingent on the proceeds that the purchaser and its affiliates receive on a subsequent sale or other capital event related to the Business (“Contingent Gain”).

In order to determine the gain on disposal related to the Business, the Company was required to make significant judgments related to the accounting treatment of the Brand Sale and the Contingent Gain, which included assessing the appropriateness of including the future payments related to the Brand Sale and Contingent Gain in the proceeds at closing and measuring the fair value of the Contingent Gain.

As a result, auditing the recognition of the Brand Sale and the recognition and measurement of the Contingent Gain required a high degree of auditor judgment and increased effort, including the involvement of specialists.

a.We tested the effectiveness of management’s controls over the accounting conclusions reached and the recognition and measurement of the Brand Sale and Contingent Gain.

b.We obtained and read the purchase and sale agreement and other documents related to the sale of the Business in evaluating the reasonableness of the Company’s recognition of the Brand Sale and the Contingent Gain.

c.With the assistance of professionals in our firm having expertise in divestiture accounting, we read and evaluated the Company’s accounting treatment for the inclusion of the Brand Sale and Contingent Gain in the proceeds from the sale of the Business at the closing date.

d.With the assistance of our fair value specialists, we confirmed the acceptability of the valuation methodology selected, and we developed an independent estimate of the fair value of the Contingent Gain and compared our estimate to the recorded amount.

February 27, 2024

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Current assets of discontinued operations | | | — | | | | | | 1,693,704 | | |

| Current liabilities of discontinued operations | | | — | | | | | | 272,865 | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Balance, January 3, 2021 | | | 112,090 | | | | | | $ | 112,090 | | | | | $ | 148,101 | | | | | $ | 3,507,262 | | | | | $ | (31,961) | | | | | $ | 3,735,492 | |

| Net income | | | — | | | | | | — | | | | | | — | | | | | | 943,157 | | | | | | — | | | | | | 943,157 | | |

| Dividends | | | — | | | | | | — | | | | | | — | | | | | | (33,245) | | | | | | — | | | | | | (33,245) | | |

| Issuance of common stock for business combination, net of issuance costs | | | 14,067 | | | | | | 14,067 | | | | | | 2,624,077 | | | | | | — | | | | | | — | | | | | | 2,638,144 | | |

| Purchases of common stock | | | (504) | | | | | | (504) | | | | | | (72,568) | | | | | | — | | | | | | — | | | | | | (73,072) | | |

| Dividends | | | — | | | | | | — | | | | | | — | | | | | | (35,335) | | | | | | — | | | | | | (35,335) | | |

| Dividends | | | — | | | | | | — | | | | | | — | | | | | | (34,900) | | | | | | — | | | | | | (34,900) | | |

| Proceeds from sale of senior unsecured notes | | | — | | | | | | — | | | | | | 3,086,095 | | |

| Settlement of swaps | | | — | | | | | | — | | | | | | (14,314) | | |

| Equity issued for business combination, net of issuance costs | | | — | | | | | | — | | | | | | 2,638,144 | | |

Effective as of April 26, 2023, the Company changed its name from “PerkinElmer, Inc.” to “Revvity, Inc.”.

Effective as of May 16, 2023, the Company changed the ticker symbol for its common stock to “RVTY” and the ticker symbol for its 1.875% Notes due 2026 to “RVTY 26”.

In March 2023, the Company completed the previously announced sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

related to the tax benefit.

The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques.

The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units.

If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill.

This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

date.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The guidance is required to be applied retrospectively to all periods presented in the financial statements, unless impracticable.

Although the guidance only requires additional disclosures, the Company is in the process of determining the impact of this guidance to its segment disclosures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December [removed: 31, 2023.][added: 29, 2024.]

The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, [added: processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms.]

Based on the evaluation of our disclosure controls and procedures as of December [removed: 31, 2023,] [added: 29, 2024,] our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

[removed: Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a] process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

Our management assessed the effectiveness of our internal control over financial reporting as of December [removed: 31, 2023.][added: 29, 2024.]

Based on this assessment, our management concluded that, as of December [removed: 31, 2023,] [added: 29, 2024,] our internal control over financial reporting was effective based on those criteria.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December [removed: 31, 2023] [added: 29, 2024] that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We have audited the internal control over financial reporting of Revvity, Inc. and subsidiaries (the “Company”) as of December [removed: 31, 2023,] [added: 29, 2024,] based on criteria established in *Internal Control—Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December [removed: 31, 2023,] [added: 29, 2024,] based on criteria established in *Internal Control – Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December [removed: 31, 2023,] [added: 29, 2024,] of the Company and our report dated February [removed: 27, 2024,] [added: 25, 2025,] expressed an unqualified opinion on those financial statements.

[removed: We believe that our audit] provides a reasonable basis for our opinion.

Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a

We believe that our audit

February 25, 2025

processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms.

February 27, 2024

During the three months ended December [removed: 31, 2023,] [added: 29, 2024,] none of our directors or officers adopted a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as the terms are defined in Item 408(a) of Regulation S-K.

[removed: The remaining information required to be disclosed by the] Item [removed: pursuant to Item 401] [added: 407] and Item [removed: 407] [added: 408(b)] of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the captions “Proposal No. 1 Election of [removed: Directors”] [added: Directors”, “Delinquent Section 16(a) Reports”] and “Information Relating to Our Board of Directors and Its Committees” and is incorporated in this annual report on Form 10-K by reference.

This information is also available in print [added: without charge] to any stockholder who requests it, by writing to Revvity, Inc., [removed: 940 Winter Street,] [added: 77 4th Avenue,] Waltham, Massachusetts 02451, Attention: Investor Relations.

The remaining information required to be disclosed by the Item pursuant to Item 401, Item 405.

The information required to be disclosed by this Item pursuant to Item 402 and Item 407(e) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the captions “Director Compensation,” “Information Relating to Our Board of Directors and Its Committees—Compensation Committee Interlocks and Insider Participation,” and “Executive Compensation,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 403 of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the caption “Beneficial Ownership of Common Stock,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 201(d) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the caption “Executive Compensation—Equity Compensation Plan Information,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 404 of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the caption “Information Relating to Our Board of Directors and Its Committees—Certain Relationships and Policies on Related Party Transactions,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 407(a) of Regulation S-K is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the caption “Information Relating to Our Board of Directors and Its Committees—Determination of Independence,” and is incorporated in this annual report on Form 10-K by reference.

The information required to be disclosed by this Item pursuant to Item 9(e) of Schedule 14A is contained in the proxy statement for our annual meeting of stockholders to be held on April [removed: 23, 2024] [added: 22, 2025] under the caption “Information Relating to Our Board of Directors and Its Committees—Independent Registered Public Accounting Firm Fees and Other Matters”, and is incorporated in this annual report on Form 10-K by reference.

Consolidated Statements of Operations for Each of the Three Fiscal Years in the Period Ended December [removed: 31, 2023][added: 29, 2024]

Consolidated Statements of Comprehensive Income for Each of the Three Fiscal Years in the Period Ended December [removed: 31, 2023][added: 29, 2024]

Consolidated Balance Sheets as of December [removed: 31, 2023] [added: 29, 2024] and [removed: January 1,] [added: December 31,] 2023

Consolidated Statements of Stockholders’ Equity for Each of the Three Fiscal Years in the Period Ended December [removed: 31, 2023][added: 29, 2024]

Consolidated Statements of Cash Flows for Each of the Three Fiscal Years in the Period Ended December [removed: 31, 2023][added: 29, 2024]

| [removed: 2.1(1)] | | | | | | [removed: [Agreement] [added: [(6) Employment Agreement between Maxwell Krakowiak] and [removed: Plan of Merger,] [added: Revvity, Inc.] dated as of [removed: July 25, 2021, by and among](http://www.sec.gov/Archives/edgar/data/31791/000119312521225700/d205775dex21.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312521225700/d205775dex21.htm)[, Inc., Burton Acquisition I, Inc., Burton Acquisition II, Inc., BioLegend, Inc. and Gene Lay, solely in his capacity as the Stockholder Representative,] [added: August 16, 2022,] filed with the Commission on [removed: July 27, 2021] [added: August 17, 2022] as Exhibit [removed: 2.1] [added: 99.1] to our current report on Form 8-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312521225700/d205775dex21.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312522222840/d57019dex991.htm)] | | | | | | | | | | | |

| [removed: 2.2(1)] [added: 2.1(1)] | | | | | | [Amended and Restated Master Purchase and Sale Agreement, dated as of March 11, 2023, by and between PerkinElmer, Inc., PerkinElmer U.S. LLC and PerkinElmer Topco, L.P. , filed with the Commission on March 16, 2023 as Exhibit 2.1 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by reference.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000031791/000119312523071549/d475595d8k.htm) | | | | | | | | | | | |

| 3.1 | | | | | | [Revvity, Inc.'s Restated Articles of Organization, [added: as amended,] filed with the Commission on [removed: May 12, 2023] [added: November 6, 2024] as Exhibit 3.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by [removed: reference.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000031791/000003179123000008/pki-20230402.htm#ib655ed8501a2415ba17d414b86275250_160)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179124000028/q3-202410qexhibit31.htm)] | | | | | | | | | | | |

| 4.1 | | | | | | [Specimen Certificate [removed: of](http://www.sec.gov/Archives/edgar/data/31791/000095013501502555/b39946peex4-1.txt) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000095013501502555/b39946peex4-1.txt)[,] [added: of Revvity,] Inc.'s Common Stock, $1 par value, filed with the Commission on August 15, 2001 as Exhibit 4.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000095013501502555/b39946peex4-1.txt)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000095013501502555/b39946peex4-1.txt)] | | | | | | | | | | | |

| 4.2 | | | | | | [Description [removed: of](http://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit42.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit42.htm)[,] [added: of Revvity,] Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, filed with the Commission on March 3, 2022 as Exhibit 4.2 to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit42.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit42.htm)] | | | | | | | | | | | |

| 4.3 | | | | | | [Indenture dated as of October 25, 2011 [removed: between](http://www.sec.gov/Archives/edgar/data/31791/000119312511284039/d247960dex991.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312511284039/d247960dex991.htm)[,] [added: between Revvity,] Inc. and U.S. Bank National Association, filed with the Commission on October 27, 2011 as Exhibit 99.1 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312511284039/d247960dex991.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312511284039/d247960dex991.htm)] | | | | | | | | | | | |

| 4.4 | | | | | | [Third Supplemental Indenture, dated as of July 19, 2016, [removed: among](http://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex42.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex42.htm)[,] [added: among Revvity,] Inc., U.S. Bank National Association, as trustee, and Elavon Financial Services DAC, UK Branch, as paying agent, filed with the Commission on July 19, 2016 as Exhibit 4.2 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex42.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex42.htm)] | | | | | | | | | | | |

| 4.5 | | | | | | [Paying Agency Agreement, dated July 19, 2016, [removed: among](http://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex43.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex43.htm)[,] [added: among Revvity,] Inc., U.S. Bank National Association, as trustee, Elavon Financial Services DAC, UK Branch, as paying agent, and Elavon Financial Services DAC, as transfer agent and registrar, filed with the Commission on July 19, 2016 as Exhibit 4.3 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex43.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312516650737/d227145dex43.htm)] | | | | | | | | | | | |

| 4.6 | | | | | | [Fifth Supplemental Indenture, dated as of September 12, 2019, by and [removed: between](http://www.sec.gov/Archives/edgar/data/31791/000119312519243941/d33594dex42.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312519243941/d33594dex42.htm)[,] [added: between Revvity,] Inc. and U.S. Bank National Association, as trustee (including the form of note contained therein) filed with the Commission on September 12, 2019 as Exhibit 4.2 to our current report on Form 8-K (File No. 001-05075)) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312519243941/d33594dex42.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312519243941/d33594dex42.htm)] | | | | | | | | | | | |

| 4.7 | | | | | | [Sixth Supplemental Indenture, dated as of March 8, 2021, by and between the Company and U.S. Bank National Association, as trustee (including the form of note contained therein) filed with the Commission on March 8, 2021 as Exhibit 4.2 to our current report on Form 8-K (File No. 001-05075)) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/0000031791/000119312521073195/d128642dex42.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/0000031791/000119312521073195/d128642dex42.htm)] | | | | | | | | | | | |

| 4.8 | | | | | | [Seventh Supplemental Indenture, dated as of September 10, 2021, by and between the Company and U.S. Bank National Association, as trustee (including the form of note contained therein) filed with the Commission on September 10, 2021 as Exhibit 4.2 to our current report on Form 8-K (file No. 001-05075)) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312521269959/d204305dex42.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/d204305dex42.htm)] | | | | | | | | | | | |

| 10.1 | | | | | | [Credit Agreement, dated as of [removed: August 24, 2021,] [added: January 7, 2025,] among Revvity, [removed: Inc., Revvity Health Sciences, Inc., Revvity Life Sciences International Holdings, Revvity Global Holdings S.à r.l.] [added: Inc.] and Revvity Health [removed: Sciences B.V.] [added: Sciences, Inc.] as Borrowers, Bank of America, N.A. as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto, filed with the Commission on [removed: August 25, 2021] [added: January 7, 2025] as Exhibit 99.1 to our current report on Form 8-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312519246865/d804222dex101.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312525002871/d915642dex991.htm)] | | | | | | | | | | | |

| [removed: 10.3*] [added: 10.2*] | | | | | | Employment Contracts: | | | | | | | | | | | |

| | | | | | | [(1) Amended and Restated Employment Agreement, dated as of August 21, 2019, between Dr. Prahlad R. Singh [removed: and](http://www.sec.gov/Archives/edgar/data/31791/000119312519226118/d794085dex991.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312519226118/d794085dex991.htm)[,] [added: and Revvity,] Inc., filed with the Commission on August 21, 2019 as Exhibit 99.1 to our current report on Form 8-K (File No. 001-05075) and incorporated herein by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312519226118/d794085dex991.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312519226118/d794085dex991.htm)] | | | | | | | | | | | |

| | | | | | | [(2) Employment Agreement between Joel S. Goldberg [removed: and](http://www.sec.gov/Archives/edgar/data/31791/000119312508171757/dex101.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312508171757/dex101.htm)[,] [added: and Revvity,] Inc. dated as of July 21, 2008, filed with the Commission on August 8, 2008 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by [removed: reference;](http://www.sec.gov/Archives/edgar/data/31791/000119312508171757/dex101.htm)] [added: reference;](https://www.sec.gov/Archives/edgar/data/31791/000119312508171757/dex101.htm)] | | | | | | | | | | | |

| | | | | | | [(3) Form of Amendment between Joel S. Goldberg [removed: and](http://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex1047.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex1047.htm)[,] [added: and Revvity,] Inc. dated as of December 3, 2010, filed with the Commission on March 1, 2011 as Exhibit 10.4(7) to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex1047.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex1047.htm)] | | | | | | | | | | | |

| | | | | | | [removed: [(4)] [added: [(5)] Employment Agreement between [removed: Daniel R. Tereau] [added: Miriame Victor] and Revvity, Inc. dated as of [removed: February] [added: January] 1, [removed: 2016,] [added: 2022,] filed with the Commission on March [removed: 1, 2016] [added: 3, 2022] as Exhibit [removed: 10.2(8)] [added: 10.3(8)] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000003179116000014/a201510kexhibit1028.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit1038.htm)] | | | | | | | | | | | |

| | | | | | | [removed: [(5)] [added: [(4)] Employment Agreement between Tajinder Vohra and Revvity, Inc. dated as of January 29, 2018, filed with the Commission on May 8, 2018 as Exhibit 10.1 to our quarterly report on Form 10-Q (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000003179118000008/pki-04012018xex_101.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179118000008/pki-04012018xex_101.htm)] | | | | | | | | | | | |

| [added: 10.10*] | | | | | | [removed: [(6) Employment Agreement between Miriame Victor and Revvity,] [added: [Revvity,] Inc. [removed: dated as of] [added: Savings Plan Amended and Restated effective] January 1, [removed: 2022,] [added: 2021,] filed with the Commission on March [removed: 3, 2022] [added: 2, 2021] as Exhibit [removed: 10.3(8)] [added: 10.16] to our annual report on Form 10-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000003179122000003/a2021exhibit1038.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179121000003/a2020exhibit1016.htm)] | | | | | | | | | | | |

| [added: 10.4*] | | | | | | [removed: [(7) Employment Agreement between Maxwell Krakowiak and Revvity, Inc. dated as of August 16, 2022,] [added: [Revvity, Inc.'s 2008 Deferred Compensation Plan,] filed with the Commission on [removed: August 17, 2022] [added: December 12, 2008] as Exhibit [removed: 99.1] [added: 10.1] to our current report on Form 8-K (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312522222840/d57019dex991.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312508252524/dex101.htm)] | | | | | | | | | | | |

| [removed: 10.4*] [added: 10.3*] | | | | | | [removed: [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312514094761/d675998ddef14a.htm)[,] [added: [Revvity,] Inc.'s 2009 Incentive Plan, filed with the Commission on March 12, 2014 as Appendix A to our definitive proxy statement on Schedule 14A (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312514094761/d675998ddef14a.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312514094761/d675998ddef14a.htm)] | | | | | | | | | | | |

| 10.5* | | | | | | [removed: [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312508252524/dex101.htm)[,] [added: [First Amendment to Revvity,] Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on [removed: December 12, 2008] [added: March 1, 2011] as Exhibit [removed: 10.1] [added: 10.9] to our [removed: current] [added: annual] report on Form [removed: 8-K] [added: 10-K] (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312508252524/dex101.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex109.htm)] | | | | | | | | | | | |

| 10.6* | | | | | | [removed: [First] [added: [Second] Amendment [removed: to](http://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex109.htm) [Revvity](http://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex109.htm)[,] [added: to Revvity,] Inc.'s 2008 Deferred Compensation Plan, filed with the Commission on [removed: March 1, 2011] [added: May 10, 2022] as Exhibit [removed: 10.9] [added: 10.1] to our [removed: annual] [added: quarterly] report on Form [removed: 10-K] [added: 10-Q] (File No. 001-05075) and herein incorporated by [removed: reference.](http://www.sec.gov/Archives/edgar/data/31791/000119312511051468/dex109.htm)] [added: reference.](https://www.sec.gov/Archives/edgar/data/31791/000003179122000006/q1-2022exhibit101.htm)] | | | | | | | | | | | |